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ABSTRACT 
 Shiga toxin-producing E. coli (STEC) are globally relevant bacterial 
pathogens responsible for epidemic outbreaks of hemorrhagic diarrhea with 
variable progression to potentially fatal systemic Shiga toxicosis.  Predictive 
clinical biomarkers and targeted therapeutic interventions for systemic Shiga 
toxicosis in diagnosed STEC patients are not available, and the impact of Shiga 
toxin production on STEC colonization and survival remain unclear.  Improved 
murine models of STEC infection are needed to address knowledge gaps 
surrounding the gastrointestinal effects of Shiga toxins, as previously published 
models utilize ablation of host defense responses or microbiota depletion to 
facilitate colonization and are poorly suited for study of the effects of Shiga toxins 
on host responses.  
 Dextran sulfate sodium (DSS) colitis in rodents has been associated with 
outgrowths of commensal E. coli in the literature, suggesting that DSS colitis 
could open a gastrointestinal niche usable by pathogenic STEC.  This DSS 
colitis-based approach successfully induced susceptibility to robust colonization 
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by two clinical isolate STEC strains in standard C57BL/6 mice.  Studies using a 
Shiga-like toxin 2 (STX2)-producing clinical isolate STEC strain and its paired 
isogenic STX2 deletion strain (STEC(ΔSTX2)) revealed that STX2 was 
associated with delayed gastrointestinal clearance of STEC and concurrent 
reduction in colonic interleukin 23 (IL-23) axis transcripts known to be critical for 
pathogen clearance in other gastrointestinal pathogen models.  In vivo reductions 
in IL-23 axis transcripts in the DSS+STEC model were supported by decreased 
IL-23 protein secretion by human macrophage-like cells during Shiga intoxication 
in vitro.  Increased morbidity during STX2-producing STEC infection was 
associated with renal injury consistent with murine systemic Shiga toxicosis 
characterized by elevations in renal transcripts of molecular injury markers and 
histologically apparent renal tubular injury in a subset of mice. 
The dissertation research establishes a novel model of DSS colitis-
facilitated murine STEC infection that recapitulates progression to systemic 
Shiga toxicosis in a subset of infected mice and demonstrates a clear STEC 
survival benefit associated with STX2 production.  Shiga toxin-induced 
suppression of IL-23 axis signaling is a novel finding facilitated by the 
DSS+STEC model, demonstrating its utility for future delineation of the impacts 
of Shiga toxins on gastrointestinal host responses to STEC. 
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CHAPTER I:  INTRODUCTION AND BACKGROUND 
Shiga toxin-producing E. coli epidemiology 
 Shiga toxin-producing E. coli (STEC) are a common cause of diarrhea in 
the United States, responsible for more than 175,000 cases and 3,200 
hospitalizations per year1,2.  Children younger than 5 years of age are particularly 
susceptible to STEC infection, with a national average of 720 hospitalizations 
annually2.  The primary reservoir of STEC bacteria are asymptomatic domestic 
ruminants, including cattle, sheep, and goats3,4.  Surveillance studies of dairy and 
beef herds have determined that STEC strains are ubiquitous in cattle herds, and 
that fecal shedding of STEC occurs frequently during times of stress like 
pregnancy or lactation5.  Sheep and goats are also reservoirs for STEC.  Human 
infection with STEC occurs via ingestion of feces-contaminated food, person to 
person fecal-oral transfer, feces-contaminated water supplies, or through direct 
contact with ruminants6,7.   
The majority of STEC patients develop hemorrhagic diarrhea that resolves 
without sequela within 5-10 days, but approximately 5-15% of STEC-infected 
patients develop a life-threatening disease known as hemolytic uremic syndrome 
(HUS)6.   HUS is a thrombotic microangiopathy characterized by acute renal 
failure, hemolytic anemia, and thrombocytopenia that presents 5-10 days after 
the onset of STEC-induced diarrhea8.  During HUS, bacterially-produced Shiga 
toxins (STXs) enter the circulation, damage endothelial cells, and promote 
formation of microthrombi in capillaries.  Bacteremia is not associated with 
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clinical HUS, and only STX-producing strains of enteropathogenic E. coli cause 
HUS9.  Tissue ischemia and mechanical red blood cell damage occur due to the 
subsequent disruption of capillary blood flow.  Renal glomerular capillaries are 
particularly affected by Shiga toxin-induced thrombotic disease, leading to acute 
renal failure characterized by severe proteinuria and oliguria8–10.  In developed 
countries, STEC-induced HUS is a leading cause of pediatric acute renal failure 
in otherwise healthy children, with incidence rates similar to sepsis, neoplasia, 
and hypovolemic shock-induced renal failure in select clinical settings11,12.  
Neurologic signs occur in 10-25% of HUS cases, ranging from mild depression 
and confusion to seizures and coma9.  Approximately 5-10% of HUS cases are 
fatal, with an estimated 30 STEC-related deaths per year in the United States13.  
Chronic morbidity is associated with about 25% of HUS cases, with renal 
insufficiency or hypertension being the most common sequelae14.  The current 
diagnostic standards for STEC infections are culture isolation of STEC or fecal 
ELISA for STXs, but fecal PCR assays for STEC-specific genomic DNA are 
being developed for clinical use15.   
Clinical management of diagnosed STEC patients is hindered by the lack 
of a validated biomarker for the prediction of systemic Shiga toxicosis-induced 
HUS during the diarrheal phase of STEC infection8,9.  The significance of this 
deficiency is compounded by the lack of approved therapeutics or interventions 
capable of preventing the onset of HUS or reducing the disease severity of active 
HUS16,17.  Clearance of STEC with antibiotic therapy is contraindicated, as 
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antibiotic therapy may be associated with an increased risk of HUS depending on 
the strain of STEC and the administered antibiotic18,19.  The benefit of 
plasmapheresis during HUS remains controversial, and treatment with the C5 
complement inhibitor Eculizumab has not shown clear clinical benefit20–22.  While 
the biochemical activity and cellular toxicity of Shiga toxins have been thoroughly 
studied over the last several decades, clinical advancements have been 
frustrated by significant gaps in knowledge regarding the in vivo progression from 
STEC-induced colitis to systemic Shiga toxin-mediated disease and HUS.  
Shiga toxin virulence factors:  genetics, structure and function 
 Shiga toxins are a family of protein virulence factors produced by multiple 
species of bacteria associated with HUS in human patients23.  Shiga toxin was 
originally discovered and characterized from Shigella dysenteriae Type 1 by Dr. 
Kiyoshi Shiga in the late 19th century24.  In 1983, two variant toxins were 
discovered in strains of emerging pathogenic enterohemorrhagic E. coli and were 
named Shiga-like toxin 1 (STX1) and Shiga-like toxin 2 (STX2)25,26.  STX1 has 
one amino acid difference with Shiga toxin, and STX2 shares 56% amino acid 
homology with STX127.  Three variants of STX2 have been identified in the 
context of human disease, termed STX2a, STX2c, and STX2d.  A fourth STX2 
variant, STX2e, effects swine and is the causative agent of porcine edema 
disease28,29.  STX1 is more cytotoxic in many cell culture systems, but purified 
STX2 isoforms exhibit greater pathogenicity in non-human primate and murine 
models30,31.  Epidemiological studies have identified a stronger association of 
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STX2-producing STEC strains with the development of HUS in human patients, 
but the wide variety of phage and E. coli genotypes have prevented a firm 
consensus regarding the relative clinical pathogenicity of the toxin subtypes32,33.  
STX1 and STX2 are contained on lysogenized bacteriophages incorporated into 
the E. coli genome independent of other pathogenicity factors34.  Various strains 
of phage have been identified that contain STX1, STX2, or multiple copies of 
toxin variants, and the origin and genomic insertion site of the incorporated 
phage in the E. coli strain may play a role in virulence35.   
Most outbreaks of STEC are caused by E. coli serotype O157:H7 strains 
that contain the locus of enterocyte effacement pathogenicity island (LEE) within 
their genome.  The LEE encodes virulence factors like intimin and type III 
secretion systems that enable attachment and effacement of the intestinal 
epithelium, inducing pedestal formation and facilitating transfer of bacterial 
proteins to epithelial cells36.  Outbreaks of STX-positive non-O157 serotype E. 
coli strains have occurred in the United States, with O26 and O111 strains being 
the most common non-O157 isolates37.  The 2011 STEC outbreak in Europe was 
caused by a novel O104:H4 E. coli strain that lacked the virulence factors found 
in typical attaching and effacing pathogenic STEC, further demonstrating the 
potential for phage transduction of a broad array of bacterial strains with STX 
genes to increase their pathogenicity38,39.  Presumably STX production is 
beneficial for STEC in the host environment due to the diversity of disease-
associated strains harboring STX-encoding phages.  While phage-encoded 
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proteins other than STXs modulate genetic expression of STEC virulence factors 
to alter growth and survival characteristics, a beneficial role of STX production for 
STEC has not been identified to date.40  The diversity of STX-containing phages, 
their mobility between strains of bacteria, and the genetic diversity of pathogenic 
E. coli susceptible to transformation by STX-containing phages suggest that 
targeting the STX virulence factor for study is the best way to achieve advances 
towards diagnosis and treatment of STEC-induced HUS patients. 
Shiga toxin family members are AB5 toxins composed of a single A 
subunit and a pentameric ring of identical B subunits (Figure 1).  The B subunits 
contain binding sites for the eukaryotic membrane glycolipid 
globotriaosylceramide (Gb3)41.  There are three Gb3 binding sites on each B 
subunit, leading to multivalent binding to multiple Gb3 moieties by each B subunit 
in the pentamer42. 
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Figure 1:  Protein structure of Shiga-like toxins. 
Graphical representation of Shiga-like toxin AB5 structure.  Pentameric B subunits 
contain binding sites for eukaryotic membrane Gb3 glycosphingolipids.  A1 portion of A 
subunit is released following cleavage by furin-like proteases and reduction of disulfide 
bond.  Free A1 contains catalytic site for depurination of 28S ribosomal rRNA.   
Reproduced from Sandvig et al.  Toxicon.  2010.43 
 
Cellular sensitivity to Shiga toxin correlates with cell membrane Gb3 
content and organization, with the exception of STX2e which binds with high 
avidity to globotetraosylceramide (Gb4)28,44,45.  Sensitive Gb3-containing cell 
lines can become resistant to STX cytotoxicity if selection occurs for Gb3-poor 
cell populations46.  Human gastrointestinal tract epithelial cells, gastrointestinal 
capillary endothelium, renal glomerular endothelium, and neurons all have 
concentrated cell membrane Gb3 content, but cellular Gb3 content and STX 
  
7
sensitivity varies between humans and other species47–51.  Binding to Gb3 leads 
to the internalization of the toxin through endocytosis and subsequent retrograde 
transport via early endosomes to the trans-Golgi network52.  Internalization via 
clathrin-dependent and clathrin-independent endocytosis have been    
reported52–54.  Transfer of STX1 from endosomes to the Golgi apparatus requires 
the endosomal sorting protein Golgi phosphoprotein 4 (GPP130), as inhibition of 
GPP130 leads to degradation of STX1 by lysosomes55.  Once it reaches the 
trans-Golgi, the toxin is transported through the Golgi apparatus to the 
endoplasmic reticulum (ER).  The AB5 holotoxin is not biologically active, but 
changes occur to the structure of the toxin during retrograde transport that 
convert the holotoxin into a catalytically active toxin subunit.  The A subunit of the 
holotoxin associates with the B subunit through non-covalent interactions and 
contains a furin protease cleavage site that is conserved in all STX variants.  
Following cleavage by furin or furin-like proteases, the AB5 structure is 
maintained by a single disulfide bond56.  The disulfide bond is reduced in the ER 
to release the catalytically active portion of the A subunit which interacts with ER 
chaperone proteins like human ER-associated DNAJ (HEDJ), 94 kDa glucose-
regulated protein (GRP94), and binding immunoglobulin protein (BiP) to facilitate 
translocation into the cytosol57,58.  The active A subunit depurinates a specific 
adenine residue within the sarcin-ricin loop of the 28S ribosomal RNA component 
of the 60S ribosome to inhibit peptide elongation59.  The catalytic site of 
depurination in the A subunit is conserved between STX variants, but variations 
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in regions adjacent to the catalytic site have been proposed as the cause of 
cytotoxic heterogeneity between STX subtypes27. The intact holotoxin is 
necessary for cytotoxicity to occur via extracellular exposure, as the B subunit 
facilitates entry into the cell and the A subunit is the effector of ribosomal toxicity.  
Inactivation of the ribosome by Shiga toxin halts protein translation and begins a 
cascade of events that lead to downstream pathways of inflammation and 
apoptosis. 
Molecular outcomes of Shiga toxicosis 
Ribosomal inactivation by Shiga toxins initiates two cellular stress 
responses known as the ribotoxic stress response (RSR) and the unfolded 
protein response (UPR).  The RSR is a signaling pathway initiated by ribotoxins 
acting on domains V or VI of the 28S rRNA that results in downstream activation 
of p38 mitogen activated protein kinase (MAPK), extracellular regulated kinase 
(ERK), and c-JUN N terminal kinase-1 (JNK1) to upregulate proinflammatory 
cytokine production depending on the cell lineage and environment60 (Figure 2).  
This response has been induced in cell culture systems by numerous ribotoxins 
including ricin, sarcin, deoxynivalenol, and Shiga toxins61.  The RSR is initiated at 
ribotoxin doses that are insufficient to globally decrease peptide synthesis, 
distinguishing it from the UPR62.    Depurination of the 28S ribosomal RNA in the 
sarcin-ricin loop is recognized by RNA-activated protein kinase R (PKR) via 
direct interaction with the damaged ribosome60,62,63.  Hematopoietic cell kinase 
(HCK) associates with PKR at the damaged ribosome to facilitate signal 
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transduction, but the direct targets of this protein complex are unknown64.  Zipper 
sterile -a-motif kinase (ZAK) is an intermediary of signal transduction between 
the PKR-HCK ribosomal complex and downstream MAPK activation65,66.  
Disruption of the RSR pathway inhibits inflammatory responses to ribotoxins in 
cell culture and limited published data suggests targeting the RSR may provide 
improved outcomes following ribotoxin exposure in vivo.  Inhibition of HCK was 
found to abrogate MAPK activation and interleukin 8 (IL-8) secretion in U937 
cells in the context of ribotoxin exposure64.  Mice globally lacking ZAK expression 
were rescued from lethal ricin exposure and rabbits treated with ZAK inhibitor 
had reduced colonic neutrophil infiltration following STEC infection66,67.   
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Figure 2:  The ribotoxic stress response (RSR) following Shiga intoxication. 
Following depurination of ribosomal rRNA by STXs, direct interaction of PKR and HCK 
with the damaged ribosome initiates RSR signaling pathway through ZAK and other 
uncharacterized mediators leading to downstream activation of effector kinases 
responsible for induction of inflammatory cytokine secretion by the intoxicated cell.  
Adapted from Hall et al.  Toxins.  2017.68 
While the RSR is induced by structural changes in ribosomes targeted by 
Shiga toxins, the UPR is a consequence of the downstream impact of ribosomal 
inactivation and inhibition of translation (Figure 3).  Depurination of the ribosome 
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terminates peptide elongation, generating unfolded or misfolded proteins.  
Accumulation of misfolded proteins causes ER stress detected by the UPR 
initiator proteins RNA-dependent protein kinase-like ER kinase (PERK), inositol-
requiring ER to nucleus signal kinase-1α (IRE1α), and activating transcription 
factor-6 (ATF6)69,70.  Early activation of IRE1α, ATF6, and PERK are 
cytoprotective via inhibition of protein synthesis and upregulation of protein and 
mRNA degradation pathways to facilitate clearance of misfolded peptides.  While 
early PERK activation promotes cellular survival, long term activation of PERK in 
the context of unresolved ER stress induces cellular apoptosis.  Chronic PERK 
activation leads to upregulation of CCAAT/enhancer-binding protein (C/EBP) 
homologous protein (CHOP) and activating transcription factor 4 (ATF4), which 
are transcription factors responsible for reinitiating protein synthesis in the late 
UPR.  If ribosomal translation is reinitiated prior to removal of unfolded proteins 
from the ER, reactive oxygen species and ER calcium fluxes are generated that 
lead to caspase 3 activation and apoptosis of the cell70.  CHOP also 
downregulates expression of the anti-apoptotic factor B-cell lymphoma 2 (Bcl-2) 
and upregulates expression of the pro-apoptotic factor Bcl-2 interacting mediator 
of cell death (BIM), further contributing to a pro-apoptotic state71.  Initiation of the 
unfolded protein response following exposure to Shiga toxin has been identified 
in cell culture systems, but the progression to cellular apoptosis varies depending 
on the intoxicated cell type72–74.  Mice injected with purified STX2 increased renal 
CHOP transcripts compared to controls, but it remains unclear if the UPR is 
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responsible for cellular damage and disease progression following Shiga toxin 
exposure in vivo75. 
 
Figure 3:  The unfolded protein response (UPR) following Shiga intoxication. 
Accumulation of unfolded or misfolded proteins following ribotoxic activity of STXs 
results in activation of UPR proteins IRE1α, PERK, and ATF6 that initiate responses to 
restore protein homeostasis.  If protein homeostasis is not restored, chronic UPR 
effectors CHOP and ATF4 initiate cellular apoptosis pathways.  Adapted from Hall et al.  
Toxins.  2017.68 
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Apoptosis and modulation of inflammatory cytokine production are 
outcomes of the RSR and the UPR associated with Shiga toxin pathogenesis in 
cell culture models, but the outcomes of intoxication vary by cell type.  Apoptotic 
caspase 8 and caspase 3 activation have been documented in several cell types 
following exposure to Shiga toxins, correlating with decreased cellular 
survival72,76,77.  In contrast, Shiga toxins fail to induce apoptosis in Gb3-rich 
human macrophage-like THP-1 cells but instead induce an inflammatory 
phenotype.  Activation of RSR effectors p38 MAPK, ERK, and JNK1 by STXs in 
THP-1 cells has been shown to upregulate expression and secretion of innate 
inflammatory cytokines tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6) 
and interleukin 1 beta (IL-1β), and the chemokines IL-8, macrophage 
inflammatory protein 1 alpha (MIP-1α), and macrophage inflammatory protein 1 
beta (MIP-1β)78–80.  Increased production of IL-1β, TNF-α, and IL-6 was observed 
in cultured human brain endothelial cells when treated with purified STX181.  
Cultured human renal endothelial cells upregulated IL6 and CXCL8 transcript 
expression after 24 hour incubations with STX1 or STX230.  Human umbilical vein 
endothelial cells incubated with STX1 and STX2 showed increased transcripts 
encoding IL-6, IL-8 and macrophage chemoattractant protein 1 (MCP1) within 4 
hours of exposure82.  In contrast, the human renal proximal tubular HK2 cell line 
did not secrete acute inflammatory cytokines or chemokines when exposed to 
STX1 or STX2 in culture despite being highly susceptible to Shiga toxin-induced 
apoptosis74.  Interestingly, acute inflammatory cytokines have been found to 
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increase the sensitivity of susceptible cells to STX-induced toxicity in culture, as 
preincubation with TNF-α or IL-1β led to increased death of human brain 
endothelial cells and human umbilical vein endothelial cells treated with STX1 or 
STX283,84.  The diversity of responses to Shiga intoxication in cell culture systems 
underscores the complexity of delineating the pathogenesis of Shiga toxin-
induced clinical disease without reliable in vivo models. 
In vivo models of Shiga toxicosis 
Various animal models of STEC infection and Shiga toxicosis have been 
reported in the literature, but a broad consensus on the most representative 
model of human STEC-induced disease has not been reached.  Despite being 
sensitive to Shiga toxins, mice are resistant to intestinal colonization by STEC8,85.  
Protein-restricted diets, antibiotic pre-treatment, germ-free conditions, and 
genetic ablation of innate immune pathways have all been used to achieve 
transient colonization of mice with STEC, but these models have not been 
broadly reproducible or are not suitable for the study of host-pathogen 
interactions86–94.  While STEC colonization in mice with intact host defenses has 
been problematic, Shiga toxin-induced disease is reproducible in mice via 
injection of purified toxins.    
Intraperitoneal injection of mice with repeated doses of purified Shiga toxin 
induces systemic STX-induced disease characterized by acute renal tubular 
injury and acute renal failure, but not thrombotic microangiopathy75,95.  
Thrombocytopenia, hemolytic anemia, and glomerular disease have not been 
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documented in mice injected with purified STX, therefore the intraperitoneal 
injection of Shiga toxin in mice is a poor recapitulation of clinical HUS.  Mouse 
renal glomerular endothelium does not contain high levels of Gb3, unlike human 
renal glomerular endothelium, likely explaining the difference in disease 
manifestation between humans and mice.51,96.  Injection of mice with bacterial 
lipopolysaccharide concurrently with STX causes glomerular disease, 
thrombocytopenia, and hemolytic anemia, reproducing many of the key elements 
of HUS91,97.  The STX+LPS model of HUS also results in severe decreases of 
circulating clotting factors and fibrinogen consistent with a consumptive 
coagulopathy in effected mice.  Thrombotic microangiopathies like HUS do not 
cause decreases in clotting factors or fibrinogen, thus making the use of the 
STX+LPS mouse model of disease a questionable recapitulation of human 
HUS98,99.  While injection of purified Shiga toxins successfully results in renal 
injury due to systemic Shiga toxicosis, these models are limited by the lack of 
other STEC virulence factors and cannot be used to study host gastrointestinal 
responses to STEC during infection.  The difficulties in establishing consistent 
STEC colonization with concurrent systemic disease in mice have led to the use 
of other animal species to model human STEC infection and HUS. 
A range of non-rodent animal models have been established for STEC 
infection and Shiga toxin-induced disease in an attempt to recapitulate human 
HUS disease conditions with or without STEC colonization.  Non-human primates 
injected intravenously with purified STX develop thrombocytopenia, hemolytic 
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anemia, glomerular injury and acute renal failure that resembles the clinical 
parameters seen in human HUS patients30,100.  Intestinal colonization of non-
human primates with STEC has not been published, and the injectable toxin 
model is limited by the lack of knowledge regarding the magnitude and duration 
of circulating Shiga toxin present in human patients.  The cost and regulatory 
burden associated with primates limit the use of the model due to the required 
specialized housing and personnel, but it is currently the best available 
recapitulation of HUS for use in preliminary therapeutic trials and HUS 
pathogenesis studies8.  Rabbits are susceptible to STEC colonization and colitis, 
but renal injury has been inconsistent depending on the breed of rabbit and the 
STEC strain101.  Injection of purified Shiga toxins resulted in thrombotic 
hemorrhage within the gastrointestinal tract and central nervous system of New 
Zealand White rabbits, but it failed to produce significant renal injury or 
glomerular thrombosis102.  Gnotobiotic piglets are susceptible to STEC 
colonization and develop gastrointestinal and neurologic disease, but fail to 
develop HUS or renal injury103–106.  Lack of immunoreagents for porcine 
specimens and the need for specialized facilities for germ-free large animal work 
has prevented this model from achieving broad application.  To date, no animal 
model has emerged that generates reproducible colonization by STEC during 
colitis with subsequent renal injury or HUS from systemic Shiga toxicosis.  The 
limitations of the currently available animal models have hindered the study of 
the host gastrointestinal immune response to STEC, but a pattern of systemic 
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and renal cytokine and chemokine alterations following challenge with STXs has 
emerged in the literature.   
Acute inflammation during Shiga toxicosis 
 Acute systemic and renal inflammatory patterns similar to those observed 
in cultured cells have been recapitulated in several animal models of STEC 
infection or STX exposure.  In non-human primates, intravenous injection of 
purified Shiga toxin caused increased transcripts encoding TNF-α, IL-6, IL-8, 
MCP-1, and MIP-1α in kidney, colon, spleen, and small intestine with concurrent 
increases in IL-6, IL-8, MIP-1α, and macrophage chemoattractant protein 1 
(MCP-1) protein in urine samples100.  Serum levels of IL-6, IL-8, MCP-1, MIP-1α, 
and granulocyte-macrophage colony stimulating factor (GM-CSF) were increased 
in baboons injected with purified STX1 and STX2, but serum TNFα levels 
remained at baseline30.  Mice injected intraperitoneally with multiple doses of 
purified Shiga toxins increased renal IL6, CCL2, CXCL1, IL1β, and TNFα 
transcripts with concurrent increases in serum protein levels95.  Citrobacter 
rodentium is a non-Shiga toxin-producing murine pathogen that forms 
gastrointestinal attaching and effacing lesions similar to clinically relevant strains 
of STEC that models enteropathogenic E. coli infection without STX 
production107.  Mice infected with a strain of C. rodentium transduced with a 
STX2d-containing bacteriophage developed increased serum protein levels of 
TNFα, interleukin 17 (IL-17), MIP-1β, MCP-1, and RANTES and renal transcripts 
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encoding IL-6, RANTES, and granulocyte colony stimulating factor (G-CSF) 
compared to mice infected with a non-transformed C. rodentium lacking STX108.   
The results of several studies suggest that systemic inflammation caused 
by exposure to purified STX or STEC infection contributes to the progression of 
disease induced by systemic Shiga toxicosis.  Mice injected with recombinant 
murine TNF-α after being injected with purified STX1 or STX2 had increased 
morbidity and mortality, but decreased morbidity and mortality when TNFα was 
given as a pretreatment 20 hours before exposure to STX1 or STX2109.    
Treatment of rats with immunosuppressive doses of dexamethasone prior to STX 
exposure reduced markers of neurologic damage and decreased numbers of 
Gb3 positive neurons compared to controls110.  Mice treated with anisodamine, 
an inhibitor of TNFα secretion in vitro, were protected from lethal doses of 
STX1111.  Baboons injected with LPS were more susceptible to development of 
HUS at low doses of STXs compared to baboons injected with STXs alone112.  
Brain samples from human cases of HUS with neurologic signs showed 
increased IL-1β levels via immunohistochemistry correlating with increased 
expression of cell membrane Gb3113.  Genetic polymorphisms in inflammation-
related genes encoding interleukin 6 receptor (IL-6R), Toll-like receptor 4 (TLR4), 
and cyclooxygenase 2 (COX2) were associated with increased risk of HUS 
development in human STEC patients114.   
While the published literature has explored the role of systemic, renal, and 
neurological inflammatory responses to Shiga toxin-mediated disease, the impact 
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of STXs on the host intestinal mucosal immune response to STEC remains 
unclear.  It is unknown if the severity or character of inflammation at the site of 
infection is a key component to the onset of systemic Shiga toxicosis.  The lack 
of reproducible murine models of intestinal STEC infection with subsequent renal 
injury remains a significant barrier to exploration of the role of Shiga toxins during 
STEC colonization and persistence within the gastrointestinal tract.  Delineation 
of Shiga toxin-induced alterations in host responses may improve future clinical 
outcomes by identifying risk factors and predictive biomarkers for systemic Shiga 
toxicosis in STEC-infected patients.  
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CHAPTER II:  DEXTRAN SULFATE SODIUM COLITIS FACILITATES 
COLONIZATION OF MICE WITH SHIGA TOXIN-PRODUCING E. COLI 
WITHOUT RESULTING IN BACTERIAL TISSUE INVASION OR 
BACTEREMIA. 
Introduction: 
A key barrier to addressing knowledge gaps regarding pathogen-host 
interactions during STEC infection is the lack of a reproducible model of murine 
STEC infection with progression to systemic Shiga toxicosis in mice with intact 
host responses.  Mice are resistant to gastrointestinal infection by STEC, as 
standard laboratory strains of mice support inconsistent rates of short term 
colonization and limited disease when infected with clinical isolate strains of 
STEC via oral gavage85,115.  Antibiotic pretreatment or caloric restriction has been 
reported to increase susceptibility to STEC colonization, but these models have 
not generated broadly reproducible results between laboratory environments92,93.  
Germ-free mice and mice with genetic ablation of the TLR signaling pathway 
component myeloid differentiation primary response 88 (MyD88) are susceptible 
to colonization with STEC followed by severe disease, but these models are not 
suitable for the study of the host gastrointestinal response to STEC or STXs due 
to the severe alterations in gut homeostasis associated with these 
conditions87,90,94.  The murine pathogen Citrobacter rodentium forms attaching 
and effacing lesions on gastrointestinal epithelium, but no naturally occurring 
STX-producing C. rodentium strains have been identified107.  Mallick et al  used 
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phage transduction to generate a STX2d-producing strain of C. rodentium which 
was capable of successfully colonizing mice with downstream STX2d-induced 
renal injury, but this model lacks other STEC virulence factors that may impact 
STX-induced disease, may have altered genetic regulation of STX production 
compared to STEC strains, and is not capable of evaluating clinically isolated 
STEC strains108.  Use of C. rodentium as a model of STEC infection is further 
weakened by recent evidence suggesting that phage regulatory proteins interact 
with the STEC genome to increase virulence independently of STX production, 
emphasizing the importance of phage-STEC interactions not included in the C. 
rodentium(STX2d+) model40. The limitations of the available mouse models of 
STEC infection preclude a thorough investigation of STEC-host interactions 
within the gastrointestinal tract, leading the Kurosawa laboratory to explore 
alternate methods of facilitating infection of a standard laboratory mouse strain 
with clinical isolate STEC strains. 
The advent of high-throughput 16S rRNA sequencing has resulted in rapid 
advances in the characterization of the intestinal microbiota of laboratory mice at 
homeostasis and during inflammatory disease.  Oral exposure to dextran sulfate 
sodium (DSS) is a well validated and frequently utilized rodent model of acute or 
chronic colitis depending on the dose and duration of exposure to DSS116.  
Huang et al found that induction of colitis with dextran sulfate sodium (DSS) 
resulted in the expansion of the commensal E. coli population in C57BL/6 
mice117.  Thus, it was reasonable to hypothesize that DSS colitis would facilitate 
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STEC colonization of DSS-sensitive C57BL/6 mice.  Colonization during DSS 
colitis would establish a STEC population in the gastrointestinal tract during 
inflammation, which approximates the conditions seen in STEC-infected patients.  
Here we describe the use of DSS colitis to facilitate colonization of C57BL/6 mice 
with a clinical isolate strain of STEC without resulting in bacteremia or significant 
tissue invasion by STEC, mimicking conditions present during clinical STEC 
infection. 
Methods 
Mice:  6-week-old male and female C57BL/6 mice were purchased from 
Charles River Laboratories (Wilmington, MA).  Mice were housed in disposable 
cages with 4 mice per cage during all experiments.  Mice were weighed and 
monitored for signs of disease daily.  Mice were euthanized if weight loss 
exceeded 20% of weight at time of oral gavage or if mouse was moribund.  Mice 
were housed and used in accordance with the guidelines and approved protocols 
of the Institutional Animal Care and Use Committee and the Institutional 
Biosafety Committee of Boston University School of Medicine. 
Bacterial strain:  STEC O157:H7 strain TW14359 (STX2a+, STX2c+, 
STX1-) was originally isolated from a patient infected via ingestion of 
contaminated spinach in Michigan, USA and was stored at -80°C in Luria Bertani 
(LB) broth (Sigma Aldrich, St. Louis, MO) prior to use118.  
DSS exposure:  MP grade DSS (MP Biomedicals, Santa Ana, CA) was 
dissolved in dH20 and then filter sterilized using a 0.22 μm PES membrane filter.  
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50 mL of sterilized DSS suspension was added to sterile disposable water bottles 
for each cage on Day 0 of experiment.  DSS suspension was replaced every 48 
hours during experiment with freshly dissolved and sterilized DSS suspension.  
Mice were randomly reassigned cages on the day of oral gavage to minimize 
cage-related variation in DSS exposure between experimental groups.  Mice that 
lost >5% of starting body weight within 5 days of starting DSS were excluded 
from experiments. 
Oral gavage:  Stock STEC strain TW14359 was used to inoculate 5 mL of 
LB broth for incubation at 37°C with 200 rpm shaking overnight.  The following 
day, broth cultures were streaked on LB agar plates (Sigma Aldrich) for 
incubation at 37°C overnight.  Isolated colonies were selected to inoculate 5 mL 
of LB broth for a 14-16 hour incubation at 37°C with 200 rpm shaking.  Cultures 
were spun at 1000x g for 10 minutes to pellet bacteria and the supernatant was 
removed.  Bacteria was resuspended in 500 μL of sterile phosphate-buffered 
saline (PBS) (GE Life Sciences, Pittsburgh, PA).  Bacterial suspensions were 
then drawn into a 1 mL syringe fitted with a gavage needle.  Mice were 
anesthetized using isoflurane (Henry Schein, Melville, NY) in a drop jar and then 
orally gavaged with 100 μL of bacterial suspension or 100 μL of sterile PBS via 
insertion of the gavage needle into the esophagus to the level of the stomach.  
Gavage suspension was serially diluted and plated on LB agar plates for 
overnight incubation at 37°C to determine CFUs administered per mouse. 
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Organ and blood cultures:  DSS-exposed mice were orally gavaged with 
0.8-1.7 x 109 CFUs of STEC strain TW14359 5 and 7 days after starting DSS.  
Mice were sacrificed 0, 2, 4, or 7 days following gavage for organ and blood 
collection.  Following sacrifice, a midline abdominal incision was made to sterilely 
expose the abdominal contents.  The distal right middle liver lobe was removed 
via sharp dissection and placed in a microcentrifuge tube on ice.  The cecum was 
reflected cranially to expose the caudal mesenteric lymph node between the 
ileum and ascending colon.  The entire caudal mesenteric lymph node was 
removed and placed in a microcentrifuge tube on ice.  The heart was exposed 
via a diaphragmatic incision and right ventricular blood was aspirated using a 25-
gauge needle on a 1 mL syringe.  Blood was streaked on blood agar plates 
(Remel, Lenexa, KS) and incubated overnight at 37°C under aerobic conditions.  
Organs were weighed and homogenized in 10 μL of PBS per mg of tissue using 
a sterile syringe plunger.  Homogenates were spun at 300x g for 5 minutes, 
supernatant was serially diluted, and dilutions were plated on blood agar for 
overnight incubation at 37°C.  Limit of detection of organ cultures was 1 x 103 
CFU/g of tissue.    
Fecal cultures on MacConkey’s:  During exposure to DSS, mice were 
isolated in sterilized cups for fecal pellet collection.  Feces were weighed, then 
homogenized in 10 μL of PBS per mg of feces using a sterile toothpick.  Solid 
components of homogenates were allowed to settle by gravity prior to serial 
dilution of supernatants in sterile PBS.  Dilutions were plated on MacConkey’s 
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with sorbitol plates (BD Biosciences, San Jose, CA) and incubated overnight at 
37°C under aerobic conditions to determine CFU / g of feces.  
Fecal qPCR:  Following oral gavage with STEC or PBS, mice were 
isolated daily for feces collection in sterile cups.  All feces produced within 15 
minutes were collected and stored at -80°C.  Fecal qPCR assay was performed 
based on previously published method used to quantify C. rodentium burden119.  
Fecal DNA was isolated from frozen samples using QIAamp DNA Stool Mini Kits 
(Qiagen, Valencia, CA) using manufacturer’s instructions.  DNA mass and purity 
were determined using a Nanodrop 2000c (Thermo Scientific, Waltham, MA) and 
diluted to 20 ng/μL in Tris-EDTA buffer (Fisher Scientific, Waltham, MA).  
Standards of STEC eae copies/g of feces were created by inoculating pre-
weighed fecal pellets from naïve mice with serial dilutions of STEC strain 
TW14359 followed by total fecal DNA isolation.  CFU/g of standards was 
determined by plating serial dilutions of STEC inoculum on LB agar plates for 
overnight incubation at 37°C.  qPCR for STEC eae was performed in 96 well 
plates using Quantifast SYBR Green qPCR Kits (Qiagen) on a StepOnePlus 
(Applied Biosystems, Foster City, CA) following manufacturer’s instructions.  50 
ng of fecal DNA was used for each qPCR reaction.  A standard curve of STEC 
eae copies/g of feces was included on each plate to quantify results, with 1 
CFU/g of feces in standard made equal to 1 copy of eae/g of feces.  Primers 
were purchased from Integrated DNA Technologies (Coralville, IA). 
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Primer Target Sequence 
eae F AAA GCG GGA GTC AAT GTA ACG 
eae R GGC GAT TAC GCG AAA GAT AC 
Table 1:  Primers used in fecal qPCR assay to determine STEC-specific eae 
copy number per g of feces. 
Results 
STEC are Gram negative facultative anaerobes capable of growing on 
MacConkey’s media under aerobic conditions, and MacConkey’s with sorbitol 
plates are used clinically to isolate STEC O157:H7 strains from clinical 
samples120.  C57BL/6 mice were found to have low numbers of fecal bacteria 
capable of growing on MacConkey’s with sorbitol media under aerobic 
conditions, with 1.8 +/- 0.7 x 105 CFU/g recovered prior to starting DSS.  
Administration of 2.5% DSS in drinking water increased the number of CFU/g of 
feces grown on MacConkey’s with sorbitol plates, reaching 2.1 +/- 0.8 x 106 
CFU/g after 5 days of DSS exposure (Figure 4).  Based on this finding, oral 
gavage timepoints of 5 and 7 days after first DSS exposure were chosen to 
evaluate STEC colonization during DSS colitis to exploit the expanding niche for 
gastrointestinal Gram negative bacterial growth. 
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Figure 4:  DSS exposure expands gastrointestinal niche for Gram negative 
bacteria in mice. 
Naïve 6-week-old C57BL/6 mice were exposed to 2.5% w/v DSS in drinking water for 5 
days.  Plot of total colonies isolated on MacConkey’s with sorbitol plates from fecal 
samples of DSS-treated mice with means +/- SE shown (N=31 mice).  Significance 
determined by one-way ANOVA with Tukey post test to day 0 CFU/g (* - p < 0.05, *** - p 
< 0.001). 
Five-day exposure to 2.5% DSS in drinking water resulted in moderate 
colitis in C57BL/6 mice gavaged with sterile PBS as determined by weight loss 
(Figure 5A). Peak weight loss of 15% of starting body weight occurred 8-9 days 
after starting DSS, followed by gradual recovery.  Minimal mortality was observed 
during DSS colitis, with only 1 out of 14 mice requiring euthanasia prior to 
experimental endpoint (Figure 5B).  Thus, 2.5% w/v DSS for 5 days appeared to 
be an appropriate dose to open a niche for STEC infection within the GI tract 
without resulting in severe colitis. 
  
28
 
Figure 5:  Exposure of 6-week-old C57BL/6 mice to 2.5% w/v DSS in drinking 
water for 5 days results in moderate colitis with minimal mortality.   
A.  Weight loss and B. Survival curves of mice exposed to 2.5% w/v DSS in drinking 
water for 5 days (N=14).  Mean +/- SE shown. 
Following exposure to 2.5% DSS for 5 days, C57BL/6 mice were 
successfully colonized via oral gavage with 0.7-3.5 x 109 CFU of STX2a and 
STX2c-producing STEC strain TW14359 0 or 2 days after DSS exposure ended 
(Figure 6A+B).  Colonization was determined via fecal qPCR for STEC specific 
eae DNA, which approximates CFU/g due to the presence of one copy of eae per 
bacterial genome.  Colonization following single oral gavage with STEC was 
robust and sustained for 7 days regardless of infection timepoint, with initial 
colonization of between 107-109 copies of eae/g of feces followed by a gradual 
decline.  Based on the finding that DSS exposure of mice opened a window of 
susceptibility to STEC colonization for multiple days, it was reasoned that 
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repeated oral gavages during DSS colitis would increase STEC burden and 
maximize STEC-induced disease. 
 
Figure 6:  Five-day exposure to 2.5% w/v DSS facilitates colonization with 
STEC.    
Mice were exposed to 2.5% w/v DSS in drinking water for 5 days followed by oral 
gavage with 0.8-1.7 x 109  CFU of STEC strain TW14359 0 or 2 days after DSS 
exposure ended.  STEC eae copies/g determined by qPCR of fecal DNA from mice 
orally gavaged with STEC A.  0 days (N=9) and B. 2 days after DSS exposure ended 
(N=8).  Means +/- SE shown.  Limit of detection of qPCR assay for fecal eae = 9.22*103 
copies / g feces.  OG = oral gavage.  BDL = below detectable limit. 
A two-hit protocol of DSS colitis + STEC infection was performed 
consisting of a 5-day exposure to 2.5% w/v DSS followed by oral gavage with 
0.8-1.7 x 109 CFUs of STEC strain TW14359 both 0 and 2 days after DSS 
exposure ended.  STEC colonization was confirmed via fecal qPCR for eae 
(Figure 7A).  The second oral gavage increased STEC burden as determined by 
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eae copies per g of feces for the two days following first oral gavage compared to 
the two days following second oral gavage, though the increase did not reach 
statistical significance due to sample size (p value = 0.06) (Figure 7B).  A 
sample size analysis of the data using G*Power software determined that 7 fecal 
samples per day were needed to detect an order of magnitude increase in 
colonization following second oral gavage in 95% of future studies121.  Thus, a 
“two hit” DSS+STEC protocol of 5 days of 2.5% DSS followed by oral gavage 
with approximately 1-5 x 109 CFUs of STEC 5 and 7 days after starting DSS was 
selected for evaluation of STEC-induced disease during DSS colitis. 
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Figure 7:  Two hit model of STEC infection increases colonization by STEC 
following DSS exposure. 
Mice were exposed to 2.5% w/v DSS in drinking water for 5 days followed by oral 
gavage with 0.8-1.7 x 109  CFU of STEC strain TW14359 both 0 and 2 days after DSS 
exposure ended.  A.  STEC eae copies/g feces determined by qPCR of fecal DNA.  
Means +/- SE shown.  B.  Box plots of eae copies/g feces days 1 and 2 following first 
oral gavage and days 3 and 4 following second oral gavage.  (PBS N = 4-12 mice per 
timepoint, STEC N = 4-12 mice per timepoint).  Limit of detection of qPCR assay for 
fecal eae = 9.22*103 copies / g feces.  OG = oral gavage.  BDL = below detectable limit.  
Statistical significance determined by one-tailed Student’s t-test. 
Bacteremia is not a recognized component of HUS in STEC-infected 
patients, and thrombotic microangiopathy is distinct from the consumptive 
coagulopathy seen during sepsis-induced disseminated intravascular 
coagulation98.  Evaluation of STEC infection models for bacteremia and STEC 
organ invasion is an important consideration, as bacteremia or sepsis would 
complicate interpretation of the effects of systemic Shiga toxicosis.  Organ 
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cultures showed minimal invasion of the liver and mesenteric lymph nodes during 
DSS colitis, regardless of STEC infection status in the two-hit model (Figure 
8A+B).  All cardiac blood cultures were negative, suggesting that bacteremia was 
not occurring during DSS colitis with concurrent STEC infection (Figure 8C).  
Thus, STEC infection via two separate oral gavage exposures during colitis 
induced by 5 days of exposure to 2.5% w/v DSS resulted in STEC colonization 
without extensive bacterial invasion or bacteremia by STEC. 
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Figure 8:  Five-day exposure to 2.5% w/v DSS followed by infection with STEC 
is not associated with bacterial invasion.   
Mice were exposed to 2.5% w/v DSS in drinking water for 5 days, then gavaged with 
PBS or 0.8-1.7 x 109 CFUs of STX2-producing STEC strain TW14359 both 0 and 2 days 
after DSS exposure ended.  Mice were sacrificed at indicated timepoints for organ and 
blood cultures.  The limit of detection of organ cultures was 1 x 103 CFU/g of tissue.  
A+B:  Total CFU/g of liver and caudal mesenteric lymph node (N=4 per group per 
timepoint).  Means +/- SE shown.  C.  Culture results from right ventricular cardiac blood 
(N = 4 per group per timepoint). 
While oral gavage exposures to STEC following 5 days of DSS exposure 
resulted in robust STEC colonization of mice during colitis, it was hypothesized 
that the duration of STEC colonization could be prolonged via maintenance 
dosing of DSS.  It was reasoned that delayed restoration of colonic homeostasis 
via continuous low-grade DSS toxicity would maintain the window of 
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susceptibility to STEC colonization and increase overall STEC burdens.  This 
approach was not successful due to the development of bacterial invasion of the 
liver and mesenteric lymph nodes of mice during DSS colitis induced by 4 days 
of exposure to 2.5% DSS followed by exposure to 1% DSS until experiment 
endpoint (Figure 9A+B). Fifty percent of mice developed bacteremia after 9 days 
of continuous DSS therapy regardless of STEC infection status, indicating that 
continuous DSS exposure directly caused extensive gastrointestinal barrier 
breach (Figure 9C). 
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Figure 9:  Continuous DSS exposure results in bacterial invasion and 
bacteremia.   
Mice were exposed to 2.5% w/v DSS for 4 days, then 1% w/v DSS in drinking water 
throughout experiment.  Oral gavage with 0.3-1.5 * 109 CFU of STX2-producing STEC 
strain TW14359 or sterile PBS was performed 5 and 7 days after starting DSS.  Mice 
were sacrificed at indicated timepoints for organ and blood cultures.  A+B.  CFU/g of 
liver and caudal mesenteric lymph node (N=2 per group per timepoint).  Means +/- SE 
shown. C.  Culture results from right ventricular cardiac blood (N = 2 per group per 
timepoint). 
A final DSS+STEC protocol for the evaluation of STEC-induced disease 
was defined as exposure to 2.5% w/v DSS for 5 days, followed by oral gavage 
with 1–5 x 109 CFU of STEC or sterile PBS 5 and 7 days after first exposure to 
DSS, as this protocol led to robust and reasonably sustained colonization with 
STEC without resulting in bacterial tissue invasion or bacteremia (Figure 10). 
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Figure 10:  Timeline of DSS+STEC model.   
Finalized time course of DSS+STEC model consisting of 5-day exposure to 2.5% 
DSS in drinking water followed by oral gavage with STEC or sterile PBS both 0 
and 2 days after DSS exposure ends.  OG = oral gavage. 
Discussion 
Colitis induced by exposure to 2.5% w/v DSS for 5 days in the drinking 
water successfully facilitated colonization by a clinical isolate STEC strain without 
resulting in bacteremia or extensive bacterial invasion of tissues outside the 
gastrointestinal tract.  There were no measurable sex-based differences in DSS-
induced weight loss, STEC colonization, or bacterial invasion during model 
development.  Colonization reached >109 copies of eae/g of feces when two oral 
gavages of approximately 1 x 109 CFUs of STEC were administered, with STEC 
persistence for 5-7 days following first gavage.  STEC colonization occurs 
reproducibly, with no failures to colonize observed in 29 mice gavaged 5 or 7 
days after starting DSS.  The DSS+STEC model successfully models key 
aspects of clinical STEC infection that have been difficult to recapitulate in mice.    
Gastrointestinal inflammation is a component of clinical STEC infection that is not 
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consistently reproduced in mouse models relying on antibiotic pretreatment or 
caloric restriction to induce susceptibility to colonization, limiting the utility of 
these infection models to explore gastrointestinal immune responses to STEC 
and Shiga toxins9,122.  STEC colonization following DSS exposure occurs in the 
context of DSS-induced colitis with possible modulation of the inflammatory 
response by STEC virulence factors, a potential benefit of this approach over 
other published STEC models.  Characterization of the effects of STXs on the 
host gastrointestinal response in the DSS+STEC model is explored in Chapter 
IV.  While epithelial damage and resulting temporary loss of epithelial defense 
functions occur during DSS colitis, host immunological and epithelial repair 
responses are present in the DSS+STEC model based on previous studies of 
short term DSS exposure models116,123.  DSS+STEC mice that survived to 
experiment endpoint successfully recovered body weight and began to clear 
gastrointestinal STEC, supporting the conclusion that the DSS+STEC model 
does not permanently ablate gastrointestinal repair responses.  Finally, tissue 
invasion and bacteremia do not occur in the DSS+STEC model, which are not 
observed during clinical STEC infection and HUS.   
Multiple factors may contribute to DSS-induced susceptibility to STEC 
colonization in mice.  The colonic microbiota is a diverse ecosystem that is 
profoundly altered during colitis, leading to dramatic changes in the bacterial 
species residing within the gut and their relative abundance that could create 
conditions favorable for STEC colonization and survival.  Antibiotic treatment and 
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caloric restriction also alter the gastrointestinal microbiota and induce 
susceptibility to STEC infection in some environments92,93.  DSS-treated mice 
with increased colonic E. coli populations also experienced an expansion of 
commensal sialidase-producing Bacteroides species with concurrent increase in 
colonic sialidase activity117.  Interestingly, mice lacking dietary sialic acid did not 
experience an outgrowth of E. coli during DSS colitis, suggesting that altered 
nutrient availability during colitis contributes to commensal E. coli expansion.  
Pathogenic E. coli O157:H7 strains are capable of utilizing free sialic acid as a 
carbon source, but do not produce sialidases124,125.  Thus, it is possible that 
alteration of the microbiota during colitis leads to increased free sialic acid and/or 
other nutrients within the colonic microenvironment that encourage STEC 
survival.   
DSS colitis-induced alterations of host defenses could also contribute to 
increased susceptibility to STEC infection.  DSS directly damages the colonic 
epithelium, with epithelial sloughing and loss of structure noted histologically prior 
to the arrival of inflammatory infiltrates116,126.  Gastrointestinal epithelial cells 
have a diverse array of functions designed to create and maintain a mucosal 
barrier to microbial pathogens.  Secreted defensin proteins, Reg proteins, mucin, 
and iron-sequestration factors like lactoferrin all contribute to the mucus barrier 
layer present at the luminal surface of the gastrointestinal tract to prevent close 
association of the microbiota with host immune cells residing within the 
mucosa127.  Host gastrointestinal epithelial cell-produced microRNA have been 
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found to be capable of promoting or inhibiting growth of specific bacterial 
species, and derangement of luminal microRNAs can impact the composition of 
the microbiota18.  Disruption of the mucosal barrier by DSS could play a role 
during STEC colonization by reduction in factors produced by mice that inhibit 
STEC colonization and survival.  Regardless of the mechanism of induced STEC 
susceptibility, the DSS+STEC model is a promising novel tool for the study of 
STEC infection.  The strength of the model would be improved if progression to 
systemic Shiga toxicosis occurred in a subset of mice during DSS+STEC 
infection, which became the logical direction of further model characterization 
experiments.   
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CHAPTER III:  SHIGA TOXIN-INDUCED MORBIDITY AND RENAL TUBULAR 
INJURY IN THE DSS+STEC MODEL 
Introduction 
The DSS+STEC model successfully establishes robust colonization of 
mice with clinical isolate strains of STEC during gastrointestinal inflammation 
without appreciable bacteremia, making it a potentially useful tool to study local 
gastrointestinal pathogen-host interactions during STEC infection.  An important 
component of murine STEC infection models is progression to Shiga toxin-
induced systemic disease in a subset of infected mice, recapitulating the clinically 
observed progression to Shiga toxin-induced HUS in a subset of STEC patients.  
The pathogenesis of progression from local gastrointestinal disease to systemic 
Shiga toxicosis remains unclear, resulting in a lack of clinically validated 
biomarkers to predict the onset of HUS in STEC-infected patients prior to the 
onset of thrombocytopenia129.  Clinical interventions that definitively reduce the 
rate of HUS in STEC patients are also not available22.  The DSS+STEC model 
could be used to address these fundamental questions regarding the 
pathogenesis of HUS if systemic Shiga toxicosis occurs in STEC-infected mice 
during DSS colitis. 
Mice infected with STEC or injected with purified STXs develop renal 
tubular injury rather than thrombotic microangiopathy and glomerular disease86.  
Similar patterns of renal injury were observed in mice infected with a C. 
rodentium strain transduced with a STX2-containing bacteriophage108.  Models of 
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murine HUS with thrombotic microangiopathy and glomerular disease rely on co-
injection of non-physiologic quantities of LPS concurrently with STXs, or the 
induction of severe colitis and bacteremia by ablating critical innate defense 
pathways, conditions which are not present in the DSS+STEC model94,97.  Thus, 
the DSS+STEC model was evaluated for the onset of renal tubular injury as an 
indicator of systemic Shiga toxicosis in mice infected with STX-producing STEC.  
Acute renal tubular injury was found to occur in a subset of mice infected with 
STX2-producing STEC during DSS colitis, but not in mice infected with an 
isogenic STX2 deletion strain of STEC or exposed to DSS without STEC 
infection. The DSS+STEC model is a novel tool for the study of systemic Shiga 
toxicosis during gastrointestinal STEC infection, as it successfully reproduces 
STEC infection followed by variable progression to Shiga toxin-induced renal 
tubular injury. 
Methods 
Mice:  Male and female C57BL/6 mice were purchased from Charles River 
Laboratories (Wilmington, MA) and housed in disposable cages (4 mice per 
cage).  Daily monitoring was performed and weights were recorded during 
experiments.  Euthanasia criteria were defined as loss of >20% of body weight at 
time of first oral gavage or if mouse was moribund.  Mice were housed and used 
in accordance with the guidelines and approved protocols of the Institutional 
Animal Care and Use Committee and the Institutional Biosafety Committee of 
Boston University School of Medicine. 
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  Bacterial Strains:  STEC strain TW14359 (STX2a+, STX2c+, STX1-) was 
originally isolated from a Michigan, USA patient and was stored at -80°C in Luria 
Bertani (LB) broth (Sigma Aldrich, St. Louis, MO) prior to use118.  STEC strain 86-
24(STX2a+, STX1-) was originally isolated from a patient in Washington, USA 
and STEC strain TUV86-2 (STX2a-, STX1-) was generated via introduction of a 
suicide plasmid containing an internal deletion spanning portions of the stx2a and 
stx2b genes into strain 86-24130,131.  STEC O157:H7 strains 86-24 and TUV86-2 
were generous gifts from Dr. John Leong (Tufts University School of Medicine, 
Boston, MA).  Both strains were stored on LB agar plates (Sigma Aldrich) at 4°C 
prior to use.  Presence or absence of stx2 and stx1 was confirmed via qPCR of 
DNA isolated from overnight cultures of each strain in 5 mL of LB broth prior to 
use in experiments.  DNA isolation was performed using a DNeasy Mini Kit 
(Qiagen), followed by qPCR using Quantifast SYBR Green qPCR Kit (Qiagen) 
with primers purchased from Integrated DNA Technologies. 
Target F sequence R sequence 
stx1 CAA GAG CGA TGT TAC GGT TTG 
GTA AGA TCA ACA 
TCT TCA GCA GTC 
stx2 GCA TCC AGA GCA GTT CTG C 
GCG TCA TCG TAT 
ACA CAG GAG 
Table 2:  Primers used in qPCR of bacterial strains to confirm STX status. 
 DSS exposure and oral gavage:  2.5 g of MP grade DSS (MP 
Biomedicals, Santa Ana, CA) was dissolved in 100 mL of dH20 and sterilized 
using a 0.22 μm PES filter (Sigma Aldrich) to make a 2.5% w/v DSS suspension.  
Mice were exposed to 2.5% w/v MP grade DSS in their drinking water for 5 days.  
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DSS suspension was replaced with freshly dissolved and filter-sterilized DSS 
every 48 hours.  After the fifth day, DSS was replaced with dH2O.  On the fourth 
day of DSS exposure, colonies of STEC strains 86-24 and TUV86-2 were 
selected to inoculate separate 5 mL LB broth cultures incubated at 37°C with 200 
rpm shaking for 14-16 hours.  Cultures were spun at 1000x g for 10 minutes to 
pellet bacteria, supernatant was removed, and bacteria resuspended in 500 μL of 
sterile phosphate buffered saline (PBS) (GE Life Sciences, Pittsburgh, PA).  Mice 
were anesthetized via isoflurane gas (Henry Schein, Melville, NY) in a drop jar 
and orally gavaged with 100 ul of bacterial suspension using a 1 mL syringe fitted 
with a gavage needle.  Control mice were gavaged with 100 μL of sterile PBS.  
Oral gavage inoculum was serially diluted, plated on LB agar plates, and 
incubated overnight at 37°C to determine bacterial CFUs administered per 
mouse.  Oral gavage was repeated 2 days after first gavage.  Separate 
experiments using STEC strain TW14359 were performed using the same 
protocol, but only a single oral gavage of STEC TW14359 was administered 
either 0 or 2 days after 5-day exposure to 2.5% w/v DSS ended.  
 Fecal qPCR:  Feces were collected during daily isolation of mice in sterile 
cups, then stored at -80°C.  Fecal DNA was isolated using QIAamp DNA Stool 
Mini Kits (Qiagen) using manufacturer’s instructions, quantified via measurement 
of 260 nm optical density in a Nanodrop 2000c (Thermo Scientific, Waltham, 
MA), and diluted to 20 ng/mL in Tris-EDTA buffer (Fisher Scientific, Waltham, 
MA).  qPCR for STEC-specific eae was performed with Quantifast SYBR Green 
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qPCR Kits (Qiagen) on a StepOnePlus (Applied Biosystems, Foster City, CA) 
using 50 ng of DNA for each PCR reaction with primers described in Chapter II, 
Table 1.  Copies of eae per g of feces were determined via qPCR of fecal DNA 
isolated from pre-weighed naïve fecal pellets spiked with a serial dilution of a 
STEC TW14359 culture.  Serial dilution of STEC culture was plated on LB agar 
plates and incubated overnight at 37°C to determine CFU/g of standards with 1 
CFU/g of feces being equal to 1 copy of eae/g of feces. 
 Renal RNA isolation and RT-qPCR:  Following euthanasia, kidneys were 
removed and the poles of both kidneys were placed in 400 μL of RNALater 
(Ambion, Waltham, MA) for fixation at 4°C for 48-72 hours.  Following fixation, 
samples were stored at -80°C.  After thawing on ice, approximately 10 mg of 
renal tissue was disrupted in 600 μL of RNeasy Plus buffer (Qiagen) with 0.143 
M β-mercaptoethanol (Sigma Aldrich) by a TissueLyser II (Qiagen) using 4 mm 
stainless steel beads at 30 Hz oscillations for 4 minutes.  RNA was isolated using 
RNeasy Plus Mini Kits (Qiagen) in a Qiacube (Qiagen) and then quantified using 
a Nanodrop 2000c.  RNA was diluted to 50 ng/μL in RNase-free water (Thermo 
Scientific), and 500 ng of RNA was used in reverse transcription reactions using 
Quantitect RT Kits (Qiagen) in a Veriti 96 well thermal cycler (Applied 
Biosystems).  Resulting cDNA was diluted to 14.3 ng/μL in Tris-EDTA for use in 
downstream qPCR reactions using Quantifast SYBR Green qPCR Kits in a 
StepOnePlus machine.  35.7 ng of cDNA was used in each qPCR reaction.  
HPRT was used as an endogenous control to account for variations in cDNA 
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input between samples.  Primers used in renal qPCR were purchased from 
Integrated DNA Technologies. 
Target F primer sequence R primer sequence 
HPRT TGG GCT TAC CTC ACT GCT TTC 
CCT GGT TCA TCA 
TCG CTA AT 
KIM1 GGA GAT ACC TGG AGT AAT CAC ACT G 
TAG CCA CGG TGC 
TCA CAA GG 
NGAL CCC TGT ATG GAA GAA CCA AGG A 
CGG TGG GGA CAG 
AGA AGA TG 
CXCL1 TCA AGA ACA TCC AGA GCT TGA AG 
GGA CAC CTT TTA 
GCA TCT TTT GG 
IL6 TCC AAT GCT CTC CTA ACA GAT AAG 
CAA GAT GAA TTG 
GAT GGT CTT G 
CCL3 TGT TTG CTG CCA AGT AGC CAC ATC 
AAC AGT GTG AAC 
TGG GAG GGA 
Table 3:  Primers used in qPCR of murine total renal cDNA. 
Renal histology:  Transverse sections of central portions of both kidneys 
were fixed in 500 μL of 10% neutral buffered formalin (Thermo Scientific) for one 
week prior to paraffin-embedding, sectioning, mounting, and staining by the 
Boston University School of Medicine Experimental Pathology Laboratory 
Services Core facility.  Hematoxylin and eosin stained slides were blindly 
evaluated for evidence of renal tubular injury as evidenced by tubular dilation, 
tubular epithelial flattening, sloughing of cells into tubular lumens, and debris 
present in tubular lumens via light microscopy using an Olympus BX51 
microscope.  Scoring was as follows:  0 = no evidence of tubular damage, 1 = 
<5% of tubules damaged, 2 = 5-15% of tubules damaged, 3 = 15-25% of tubules 
damaged, 4 = >25% of tubules damaged.  Periodic acid Schiff-stained slides 
were blindly evaluated for presence of renal cortical tubular brush borders.  
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Brush border status of 200 tubules per sample were determined at 200X 
magnification to quantify the number of brush border negative tubules.  At least 5 
fields were counted per sample. 
 Serum BUN and creatinine:  Blood was collected from the facial vein at 
time of sacrifice and allowed to clot at room temperature for 30 minutes.  Blood 
was spun at 1000x g for 10 minutes followed by collection of serum for storage at 
-80°C.  BUN concentration was determined using a Quantichrom Urea Assay Kit 
(Bioassay Systems) in a 96 well plate using manufacturer’s instructions.  Serum 
creatinine was determined using a Quantichrom Creatinine Assay Kit (Bioassay 
Systems).  Absorbance was measured using a VersaMax microplate reader 
(Bioassay Systems).   
 Statistical analysis:  Data were analyzed using GraphPad PRISM as 
described in figure legends. 
Results 
Shiga toxin induced morbidity and renal injury were evaluated in the 
DSS+STEC model using the STX2a-producing clinical isolate STEC O157:H7 
strain 86-24 and its isogenic STX2a deletion (ΔSTX2) strain TUV86-2.  
STEC(ΔSTX2) strain TUV86-2 was generated through suicide plasmid mediated 
deletion of portions of the stx2a and stx2b genes in the parent 86-24 strain to 
create paired STEC strains with identical virulence factors other than STX2 
production131.  Mice exposed to 5 days of 2.5% w/v DSS were orally gavaged 
with either STEC strain 86-24, STEC(ΔSTX2) strain TUV86-2, or sterile PBS on 
  
47
day 0 and 2 after DSS exposure ended.  Both bacterial strains successfully 
colonized mice with similar rates of colonization observed for the first three days 
after initial infection (Figure 11A).  This allowed for comparison of disease 
induced by both strains during DSS colitis.  PBS-gavaged mice did not have 
detectable fecal eae at any timepoint, as expected.  Interestingly, STX2-
producing STEC strain 86-24 exhibited delayed clearance during DSS colitis 
compared to ΔSTX2 strain TUV86-2.  Difference in clearance was noted 4 days 
after infection, and clearance remained delayed until 6 days post-infection 
(Figure 11B-D).   
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Figure 11:  STX2a production does not affect initial colonization but delays 
clearance of STEC during DSS colitis. 
C57BL/6 mice were exposed to 2.5% w/v DSS in drinking water for 5 days followed by 
oral gavage with 3.4-5.5 x 109 CFU of STX2-producing STEC strain 86-24 (STEC) or 
3.3-4.6 x 109 CFU of isogenic STX2 deletion strain TUV86-2 (STEC(ΔSTX2)) suspended 
in 100 μL of PBS.  Control mice were orally gavaged with sterile PBS.  Repeat oral 
gavage of respective STEC strains or PBS was administered 2 days later.  Mice were 
followed for 7 days after infection.  A.  STEC eae copy number determined by qPCR of 
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fecal DNA from DSS-treated mice gavaged with STEC (N=12), STEC(ΔSTX2) (N=12), 
or PBS (N=9).  B-D.  Box plot distributions of colonization on indicated days following 
infection.  Limit of detection = 9.22 x 103 eae copies / g feces.  OG = oral gavage.  BDL 
= below detectable limit.  Means +/- SE shown. Statistical significance determined by 
two-tailed Student’s t-test (** - p < 0.01). 
Mice gavaged with STX2a-producing STEC strain 86-24 experienced 
increased morbidity and 66% of mice met euthanasia criteria within 5 days of 
infection (Figure 12A).  Both PBS-gavaged and STEC(ΔSTX2)-gavaged mice 
experienced minimal mortality.  While total baseline weight loss was not 
significantly increased in STEC-infected mice, the rate of weight loss was greater 
in STEC-infected mice between 3 and 4 days after infection, when the most 
severely affected mice met euthanasia criteria (Figure 12B+C). 
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Figure 12:  STEC infection with STX2 production during DSS colitis increases 
morbidity.   
Mice were orally gavaged with STX2-producing STEC strain 86-24, STEC(ΔSTX2) strain 
TUV86-2, or PBS on days 0 and 2 following 5-day exposure to 2.5% w/v DSS.  A.  
Survival curves of DSS+STEC mice.  Mice were euthanized based on clinical 
appearance and weight loss.  Statistical significance determined via Mantel-Cox test.  B:  
Percent gavage weight curves.  C.  Rate of weight loss between days 3 and 4 following 
first oral gavage.  OG = oral gavage.  STEC-infected mice (N = 12), STEC(ΔSTX2)-
infected mice (N = 12), PBS control mice (N = 9). Means +/- SE shown.  Statistical 
significance determined by one-way ANOVA with Tukey post test. (* - < 0.05). 
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STEC-infected mice were stratified by euthanasia timepoint to determine if 
increased morbidity was associated with renal tubular injury, as would be 
expected during systemic Shiga toxicosis.  Renal samples were collected 
between days 3 and 5 after oral gavage in euthanized mice infected with STX2a-
producing strain 86-24.  Surviving mice were sacrificed for sample collection 7 
days after infection.  Transcript levels of molecular markers kidney injury 
molecule 1 (KIM1) and neutrophil gelatinase associated ligand (NGAL) are 
frequently used to quantify renal injury in murine models, as renal KIM1 and 
NGAL transcripts are known to be elevated prior to the onset of histologically 
evident renal tubular injury132.  Increased morbidity in a subset of mice colonized 
by STX2a-producing STEC strain 86-24 during DSS colitis was associated with 
significantly higher renal transcripts of NGAL and KIM1 at time of euthanasia 
compared to mice with DSS colitis alone (Figure 13A+B).   
The elevations in KIM1 and NGAL correlated with histologically apparent 
renal injury in DSS+STEC mice (Spearman r = 0.926, p < 0.001).  STEC-infected 
mice with elevations in KIM1 and NGAL transcripts exhibited evidence of renal 
cortical tubular injury characterized by tubular dilation, flattening of tubular 
epithelium, and sloughing of cells into tubular lumens (Figure 13C).  Tubular 
injury was only seen in mice infected with STX2-producing STEC strain 86-24 
during DSS colitis, kidneys from mice infected with STEC(ΔSTX2) strain TUV86-
2 during DSS colitis appeared normal histologically (Figure 13D).  Morbidity as 
determined by euthanasia timepoint was similar between male and female mice, 
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with histologically apparent renal tubular injury occurring in 1 out of 4 male 
STEC-infected mice and 3 out of 8 female STEC-infected mice.  The renal cortex 
contains a mixture of brush border positive proximal convoluted tubules and 
brush border negative distal convoluted tubules, but proximal tubules will lose 
brush border expression during acute renal tubular injury133,134.  Increased 
morbidity during DSS colitis and concurrent STX2a-producing STEC 86-24 
infection was associated with a higher percentage of renal cortical tubules 
without brush borders as determined by blinded evaluation of PAS-stained slides 
(Figure 13E).  Thus, early structural renal tubular injury was associated with 
morbidity in a subset of mice infected with STX2a-producing STEC 86-24 during 
DSS colitis, correlating with increases in renal transcripts of KIM1 and NGAL. 
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Figure 13:  Renal tubular injury is associated with STX2 production and 
increased morbidity in DSS+STEC model. 
Mice were orally gavaged with STX2-producing STEC strain 86-24, STEC(ΔSTX2) strain 
TUV86-2, or PBS on days 0 and 2 following 5-day exposure to 2.5% w/v DSS.  A+B.  
Fold change of total renal KIM1 and NGAL transcripts normalized to DSS+PBS 
transcript content determined by RT-qPCR.  C. Representative 150X images with 600X 
  
54
insets of H&E stained renal cortex from DSS+PBS, DSS+STEC, and 
DSS+STEC(ΔSTX2) mice showing renal tubular dilation and epithelial flattening in 
STEC-infected mice (arrows).  Images are from mice euthanized 3-4 days after infection.  
D.  Tubular injury scoring.  Statistical significance of histological scoring determined by 
Kruskal-Wallis test.  E.  Percent of renal tubules lacking intact PAS+ brush borders.  
PBS controls (N=9), STEC Live (N=4), STEC Euth (N = 8), STEC(ΔSTX2) (N=12).  
Means +/- SE shown in bar graphs.  Statistical significance determined by one-way 
ANOVA analysis with Tukey post test.    (* - p < 0.05, ** - p < 0.01, *** - p < 0.001). 
Tubular injury induced by STX2a-producing STEC infection during DSS 
colitis appeared to be due to direct STX action on renal tubules rather than 
tubular injury secondary to severe colitis or hypovolemia.  During pilot 
experiments to determine the optimal DSS exposure to facilitate STEC 
colonization without inducing severe colitis, a group of mice were exposed to 
2.5% DSS for 5 days followed by continued 1% w/v DSS in drinking water until 
experiment endpoint.   The increased exposure to DSS resulted in severe colitis, 
requiring euthanasia between 4 and 5 days after gavage with PBS.  As shown in 
Figure 9A, a small number of mice gavaged with PBS or STEC(ΔSTX2) strain 
TUV86-2 following 5-day exposure to 2.5% DSS also met euthanasia criteria 3-4 
days after gavage.  As a group, mice meeting early euthanasia criteria during 
colitis without STX2-producing STEC infection had similar mortality and weight 
loss curves as euthanized mice infected with STX2-producing STEC strain 86-24 
(Figure 14A+B). Importantly, renal KIM1 transcripts in mice euthanized during 
severe colitis without STX-producing STEC infection were not elevated 
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compared to naïve mouse kidneys (Figure 14C).  Renal NGAL transcripts were 
mildly elevated in mice requiring early euthanasia due to severe DSS colitis, but 
the increase in NGAL was significantly lower than mice requiring early 
euthanasia during STX2-producing STEC 86-24 infection (Figure 14D).  Mild 
elevations in NGAL during severe colitis are to be expected, as systemic 
inflammation is known to increase renal NGAL expression without any other 
evidence of renal injury132.  These findings support the conclusion that renal 
tubular injury during STEC infection was due to circulating STX2a rather than 
hypovolemic disruptions of renal blood flow or systemic inflammation secondary 
to severe colitis.    
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Figure 14:  Severe colitis-induced morbidity without STX2-producing STEC 
infection does not result in renal injury in DSS+STEC model.   
All mice meeting euthanasia criteria prior to experimental endpoint in the DSS+STEC 
model were included for analysis.  Mice exposed to 2.5% w/v DSS for 5 days (solid box) 
followed by exposure to 1% w/v DSS until experiment endpoint (dotted box) were 
gavaged with PBS 5 and 7 days after starting DSS (N = 3).  Other mice were exposed to 
5 days of 2.5% DSS followed by dH2O until experimental endpoint and gavaged with 
PBS (N = 1), STEC(ΔSTX2) strain TUV86-2 (N = 2), or STX2a-producing STEC strain 
86-24 (N=8) 0 and 2 days after DSS exposure ended.  A.  Survival curves of Non-STEC 
(mice gavaged with PBS or STEC(ΔSTX2)) compared to STEC-gavaged mice.  B.  
Percent gavage weight curves.  C+D.  Renal KIM1 and NGAL transcripts determined by 
RT-qPCR normalized to naïve mouse kidney transcript content.  OG = oral gavage.  
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Means +/- SE shown.  Non-STEC (N=6), STEC (N = 8), Naïve (N=5).  Statistical 
significance determined by one-way ANOVA with Tukey post test.  (** - p value < 0.01, * 
- p value < 0.05).     
 Renal inflammation occurs in murine and non-human primate models of 
Shiga intoxication, with increased renal transcripts of acute inflammatory 
cytokines and chemokines occurring following injection of purified Shiga 
toxins95,100.  Increased morbidity in mice infected with STX2a-producing STEC 
strain 86-24 during DSS colitis was associated with increased renal IL6 and 
CXCL1 transcripts, similar to previously published data in mice injected with 
purified STX2 (Figure 15A+B).  Renal CCL3 transcripts encoding for the C-C 
chemokine MIP-1α were not statistically different between groups, suggesting 
that STX2a does not induce CCL3 upregulation in the DSS+STEC model or that 
CCL3 induction occurs at a later timepoint during STX2-driven renal injury than 
CXCL1 and IL6 (Figure 15C).   
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Figure 15:  STX2 production is associated with acute renal inflammation in 
DSS+STEC model. 
Mice were orally gavaged with STX2-producing STEC strain 86-24, STEC(ΔSTX2) strain 
TUV86-2, or PBS on days 0 and 2 following 5-day exposure to 2.5% w/v DSS.  Fold 
change of total renal transcripts of A.  CXCL1  B.  IL6  C.  CCL3.  All fold changes 
normalized to DSS+PBS control renal transcript content determined by RT-qPCR.  PBS 
controls (N = 9), STEC Live (N =4), STEC Euth (N = 8), STEC(ΔSTX2) (N = 12).  Means 
+/- SE shown.  Statistical significance determined by one-way ANOVA with Tukey post 
test.  (*** - p < 0.001). 
The severity of histologically apparent renal tubular injury was mild, which 
was supported by the finding of modest increases in BUN observed during 
increased morbidity in mice infected with STX2a-producing strain 86-24 during 
DSS colitis (Figure 16A).  Serum creatinine was not found to be elevated in any 
group in the DSS+STEC model, further supporting the conclusion that renal 
injury was mild and did not progress to acute renal failure by the time of 
euthanasia (data not shown).  Mild to moderate increases in BUN support the 
conclusion that severe dehydration did not occur in the DSS+STEC model, as 
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azotemia is a well- established clinical marker of dehydration.  Taken together, 
elevations in molecular markers of renal injury, histologically evident renal tubular 
damage, and elevations in renal inflammatory transcripts are all consistent with 
early or mild STX2a-induced renal injury in a subset of mice in the DSS+STEC 
model.  No evidence of renal injury occurred during severe DSS colitis or 
infection with STEC(ΔSTX2) strain TUV86-2, indicating that STX2a was the 
direct agent of renal injury rather than systemic inflammation secondary to 
severe colitis or altered renal blood flow due to hypovolemia/dehydration. 
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Figure 16:  Mildly increased serum BUN is associated with STX2 production and 
increased morbidity in DSS+STEC model.   
Mice were orally gavaged with STX2-producing STEC strain 86-24, STEC(ΔSTX2) strain 
TUV86-2, or PBS on days 0 and 2 following 5-day exposure to 2.5% w/v DSS.  Serum 
BUN was measured at time of sacrifice.  PBS controls (N=9), STEC Live (N=4), STEC 
Euth (N = 8), STEC(ΔSTX2) (N=12).  Statistical significance determined by one-way 
ANOVA with Tukey post test (* - p value < 0.05).   
 Overall, 4 out of 12 mice developed renal tubular injury in the DSS+STEC 
model following two exposures to STX2a-producing STEC strain 86-24 via oral 
gavage.  The rate of renal injury in mice exposed to 2.5% w/v DSS for 5 days 
followed by a single oral gavage with STX2a and STX2c-producing STEC strain 
TW14359 was lower, as would be expected if total STEC burden and STX2 
production was responsible for renal injury.  Only 3 out of 17 mice required early 
euthanasia with evidence of early renal disease characterized by elevated renal 
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KIM1 and NGAL transcripts and histological evidence of renal tubular disease in 
mice exposed to a single oral gavage of STEC (Figure 17A-D).  The magnitude 
of colonization with STX2-producing STEC correlated with the rate of systemic 
Shiga toxicosis as evidenced by renal tubular injury in the DSS+STEC model, 
which strengthens the conclusion that STX2 is the cause of renal injury. 
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Mice were exposed to 2.5% w/v DSS in drinking water for 5 days followed by oral 
gavage with a single dose of 0.7-3.5 x 10  CFUs of STX2-producing STEC strain 
TW14359 either 0 or 2 days after DSS exposure ended.  Controls were gavaged with 
sterile PBS.  A.  Survival curves.  B-C.  Renal transcript fold changes of molecular injury 
markers KIM1 and NGAL normalized to DSS+PBS controls.  D.  Representative 150X 
images with 600X insets of H&E stained renal cortex from mice administered single oral 
gavage of PBS or STEC.  Arrows indicate renal tubular damage characterized by tubular 
dilation and epithelial flattening in the most severely affected STEC-infected mouse.  
PBS control (N = 5), STEC (N =17), STEC Live (N=14), STEC Euth (N = 3).  Means +/- 
SE shown in bar graphs.  Statistical significance determined by one-way ANOVAs with 
Tukey post test.  (* - p < 0.05, ** - p < 0.01). 
  
 
Figure 17:  Single oral gavage with STEC following DSS exposure results in low 
rates of renal injury. 
9
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Discussion 
The DSS+STEC model reproducib
gastrointestin
toxicosis or clearance of STEC without systemic disease, similar to 
outcomes observed in STEC patients clinically.  STX2 production by STEC in
gastrointestinal tract during DSS colitis was associated with increased mor
and evidence of early or mild renal tubular injury in a subset of infected mice, 
correlating with progression to systemic Shiga toxicosis and HUS in a subset of 
human STEC patients.  The two hit DSS+STEC model resulted in 33% of 
infected mice developing systemic Shiga toxicosis, which is higher than the 5-
10% incidence of HUS in hospitalized patients occurring in most STEC 
outbreaks6,118.   
 The pattern of renal injury observed in the DSS+STEC model is s
renal tubul inju
C. rodentium transduced with STX2d-producing phage95,108.  It is reasonable to 
propose that early euthanasia of mice due to weight loss and morbidity prevented
progression of renal tubular injury to the point of renal insufficiency.  At the time 
of euthanasia, STEC-infected mice still had a significant bacterial burden of > 108 
copies of eae per g of feces, suggesting that continued STX2a exposure would 
occur if mice were not sacrificed.  Increased morbidity in DSS+STEC mice likely 
was associated with multiple factors associated with STX2a production including
worsened colitis and systemic inflammation, as the degree of renal tubular injury 
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nced by renal tubular injury, but it is not a model of HUS.  Renal 
 
d 
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ury, 
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 systemic 
observed was not severe enough to explain increased morbidity alone at time of 
euthanasia.    
 It is important to note that the DSS+STEC model results in systemic Shiga
toxicosis evide
glomeruli of STEC-infected mice appeared normal histologically, and there was 
no evidence of thrombosis or fibrin deposition in the kidney.  Mice injected with 
high doses of STXs do not develop glomerular injury without concurrent injection
with non-physiologic doses of LPS, making it unlikely that glomerular injury woul
occur during STEC colonization of the gastrointestinal tract97.  Injection of 
LPS+STXs is a poor model of HUS, as it leads to global decreases in clotting 
factors and fibrinogen more consistent with disseminated intravascular 
coagulation than HUS. HUS patients have normal to elevated fibrinogen and 
other clotting factors despite thrombocytopenia98.  In contrast to mice, n
human primates injected with STXs develop thrombocytopenia, glomerular inj
and maintain their circulating fibrinogen levels30.  Primates remain the best 
animal system for Shiga toxin-induced HUS as a disease, but the costs 
associated with primate research have prevented development of a full mod
STEC gastrointestinal infection with progression to HUS from STEC-prod
STXs.  STEC infection during DSS colitis models the progression of 
gastrointestinal STEC infection to systemic Shiga toxicosis, providing a novel to
for the exploration of gastrointestinal disease factors that contribute to
Shiga toxicosis.  
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CTION ON COLITIS AND THE INTERLEUKIN 23 AXIS 
Introduction 
 Previously published models of murine STEC infection are poorly suited to 
investigate pathogen-host interactions in the gastrointestinal tract due to variable 
rates of colonization, lack of gastrointestinal inflammation following STEC 
infection, or the suppression of host immunological responses to induce 
susceptibility to STEC colonization122.  The DSS+STEC model successfully 
establishes STEC colonization in mice during gastrointestinal inflammation 
without permanently ablating epithelial or immunological host defense responses, 
making it a potentially useful tool to explore the impact of STXs on host 
responses during STEC infection.  The impact of STXs on the gastrointestinal 
tract during STEC infection are incompletely characterized, and knowledge gaps 
regarding gastrointestinal host responses during STEC infection have hindered 
identification of predictive biomarkers and preventative interventions in STEC 
patients prior to the onset of systemic Shiga toxicosis and HUS.      
The intestinal mucosa is constantly exposed to the bacterial population 
present within the lumen of the gut, stimulating localized immunological 
responses to maintain microenvironment homeostasis and clear potential 
pathogens.  Extracellular microbes that penetrate the mucus layer and interact 
with the intestinal epithelial surface induce several components of mucosal 
immunity referred to as the interleukin 23/interleukin 17 axis.  Stimulation of 
CHAPTER IV:  EFFECTS OF STEC INFECTION AND SHIGA TOXIN 
PRODU
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n recognition receptors (PRRs) on gastrointestinal epithelial cells, dend
 macrophages leads to secretion of IL-23 along with other acute 
cytokines inclu
nucleotide-binding oligomerization domain-containing protein 2 (NOD2), and 
dectin-1 stimulation are known to generate strong IL-23 responses, but Toll-like 
receptor 4 (TLR4) and other PRR signaling pathways are also capable of 
inducing IL-23 secretion135.  IL-23 is a heterodimer comprised of one uniq
subunit (IL23p19) and one subunit shared with interleukin 12 (IL-12) (IL12p4
that are transcribed and translated independently.  The IL-23 receptor (IL-23
expressed by lymphocyte subclasses that are broadly categorized as Type 17 
lymphocytes defined by expression of the master transcription factor reti
receptor-related orphan receptor-γt (RORγt)136.  Lamina propria and 
intraepithelial CD3- T cells that express RORγt and IL-23R are categorized as 
class 3 innate lymphocytes responsible for the rapid secretion of IL-17, IL-22 and
other cytokines following stimulation with IL-23 or IL-1β.  Subsets of δ T cells
and natural killer cells are also responsible for IL-22 and IL-17 secre
se to cytokine stimulation.  Naïve CD4+ T cells activated in the presence
of IL-1β, IL-6, and transforming growth factor beta (TGF-β) upregulate R
differentiate into effector Th17 cells that secrete IL-17 and IL-22 to amplify 
response 137,138.  IL-17 induces CXC chemokine and granulocyte colony 
stimulating factor (G-CSF) secretion by IL-17 receptor-expressing epithelium
endothelium, fibroblasts, and macrophages to increase release of neutrophils
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from the bone marrow and chemotactically recruit neutrophils to the site of 
infection137,139.  IL-22 binds IL-22 receptors on epithelial cells to increase b
functions including secretion of antimicrobial proteins by enterocytes and muc
production by epithelial goblet cells137,140.  Gastrointestinal epithelial cells also
express IL-23R, and stimulation by IL-23 contributes to epithelial barrier 
functions141.  The combination of phagocyte recruitment and increased ant
microbial epithelial functions are key contributors to the effective clearance of
extracellular microbes from the mucosa to restore the gastrointestinal epithelial 
barrier and gut homeostasis. 
STEC generally associate with the intestinal epithelium and are not 
thought to infiltrate the mucosa in human patients.  The murine pathogen 
Citrobacter rodentium causes similar epithelial lesions in mice, makin
potential model for host responses to attaching and effacing strains of STEC.  
Atarashi et al found that adherence of C. rodentium to the intestinal epithelium 
leads to induction of IL-17 secreting CD4+ T cells in the lamina propria, with 
increased tissue expression of Th17-associated transcripts IL-17, IL-22, and
21.  STEC infection of germ-free mice induced a weak Th17 response, likely due
to sporadic formation of attaching and effacing lesions compared to C. rodentium
infection87.  The STEC strain used in the studies was a STX knockout strain, th
the impact of toxin secretion on the immune response was not investigate
Peak colonic IL-23 and IL-22 transcript and protein secretion occurs within 4 
days of infection with C. rodentium, and genetic ablation of IL-23 or IL-22 
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cytokine production results in mortality140.  Mice infected with a strain of C. 
rodentium genetically altered to produce STX2 had elevated serum IL-17 levels 
compared to mice infected with C. rodentium lacking STX2 production, but 
cytokine dynamics within the gastrointestinal tract were not evaluated108.  The 
interleukin 23 axis appears critical to host defense responses to bacteria 
form close associations with gastrointestinal epithelium like STEC, but the IL
axis response during STEC infection with STX production has not been 
determined. 
As discussed in Chapter III, the D
ce between STX2a-producing STEC and an isogenic STX2a deletio
strain of STEC, which suggests that STX2a inhibited host responses nece
for STEC clearance during DSS colitis.  Here we describe STX2a-induced 
reductions in IL-23 axis colonic transcripts correlating with worsened histologica
gastrointestinal epithelial damage in the DSS+STEC model.  Reduced IL-23 
protein secretion following LPS stimulation was found in toxin-sensitive huma
macrophage-like cells during Shiga intoxication, supporting the hypothesis that 
STXs inhibit IL-23 secretion by sensitive phagocytes, which then reduce 
downstream Type 17 lymphocyte responses.  These early data show that the 
DSS+STEC model is capable of delineating the effects of STX production on 
gastrointestinal host responses that contribute to STEC clearance, which is 
crucial for the understanding of the pathogenesis of Shiga toxicosis. 
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A) was 
dissolved in dH20 (2.5 g per 100 ml H2O) to make a 2.5% w/v suspension.  DSS 
Methods 
 Mice:  Male and female 6-week-old C57BL/6 mice were purchased from 
Charles River Laboratories (Wilmington, MA) and housed in disposable cag
mice per cage).  Weight and clinical observations of each mouse were recorde
daily.  Mice were euthanized if they lost > 20% of gavage body weight or if the
mouse appeared moribund.  Mice were housed and used in accordance with the 
guidelines and approved protocols of the Institutional Animal Care and U
Committee an
icine. 
 Bacterial strains and Shiga toxins:  STEC O157:H7 strain TW14359 
(STX2a+, STX2c+, STX1-) was originally isolated from a Michigan, USA 
patient118.  STEC O157:H7 strain 86-24 (STX2a+, STX1-) was originally iso
from a Washington, USA patient and its isogenic STX2a deletion strain TUV86-2 
was generated using a suicide plasmid containing a genetic sequence with an
internal deletion of portions of the genes encoding the STX2a a and b 
subunits130,131.  Strains 86-24 and TUV86-2 were generous gifts from Dr. John 
Leong (Tufts University School of Medicine, Boston, MA).  Purified STX1 
STX2 were purchased from the Phoenix Laboratory at Tufts University School 
Medicine.  LPS was removed from STXs via incubation with polymyxin-agaros
beads (Sigma Aldrich, St. Louis, MO) prior to use. 
 DSS exposure:  MP grade DSS (MP Biomedicals, Sana Ana, C
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 was sterilized with a 0.22 μm PES filter (Sigma Aldrich) and then 50 
 
d 
ernight incubation at 37°C with 200 rpm shaking in a floor 
 
o 
rawn into 
 determined by plating serial 
suspension
ml was added to sterile disposable water bottles.  DSS suspension was replaced
with freshly dissolved and sterilized DSS suspension every 48 hours.  After 5 
days of exposure, DSS suspension was replaced with dH20 until experiment 
endpoint.  Mice losing >5% of starting body weight by the fifth day of DSS 
exposure were excluded from experiment. 
 Oral gavage with STEC:  Stocks of STEC strains TW14359, 86-24, an
TUV86-2 were used to inoculate 5 ml of sterile Luria Bertani (LB) broth (Sigma 
Aldrich) for ov
incubator.  Overnight cultures were streaked on LB agar (Sigma Aldrich) for
overnight incubation at 37°C.  The following day, colonies were selected t
inoculate 5 ml of sterile LB broth for incubation at 37°C with 200 rpm shaking for 
14-16 hours.  After incubation, cultures were spun at 1000x g to pellet bacteria, 
supernatant was aspirated, and bacteria were resuspended in 500 μL of sterile 
PBS (GE Life Sciences, Pittsburgh, PA).  Bacterial suspensions were d
a 1 mL syringe fitted with a gavage needle.  Mice were anesthetized with 
isoflurane gas (Henry Schein, Melville, NY) in a drop jar.  Oral gavage was 
performed with 100 μL of bacterial suspension administered via gavage needle 
inserted into the esophagus to the level of the stomach.  Control mice were 
gavaged with sterile PBS.  CFUs administered were
dilutions of gavage suspension on LB agar plates for overnight incubation at 
37°C.  Mice were gavaged with 0.8-1.7 x 109 CFUs of STEC strain TW14359, 
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3.4-5.5 x 109 CFUs of STEC strain 86-24, or 3.3-4.6 x 109 CFUs of STEC strain 
TUV86-2 on day 0 and 2 following 5-day exposure to 2.5% w/v DSS. 
 Colon lengths:  Following sacrifice, midline abdominal incision was mad
and colon was removed via sharp dissection.  Entire colon length was measu
from cecocolic junction to pelvic inlet. 
 Fecal occult blood testing:  Following
pellets were collected during daily isolation of mice and tested using a SureVue
fecal occult blood kit (Fisher HealthCare, Houston, TX).  Presence of fecal occu
blood was recorded as positive or negative. 
 Colonic RNA isolation and RT-qPCR:  Following sacrifice, 3-4 mm 
segments of the proximal and distal colon were removed via sharp dissectio
and submerged in 400 μL of RNAlater (Ambion, Waltham, MA) for fixation at 4°C 
for 48-96 hours.  Following fixation, tissues were stored at -80°C.  A 1 mm 
segment of proximal colon and 1 mm segment of distal colon were disrupted and 
homogenized in RLTPlus buffer (Qiagen, Valencia, CA) with 0.143 M β-
mercaptoethanol (MP Biomedical) using 4 mm stainless steel beads in a 
Tissuelyser II (Qiagen) operated at 30 Hz oscillation for 4 minutes.  RNA wa
isolated using a RNeasy Plus Mini Kit (Qiagen) in a Qiacube (Qiagen).  RNA wa
quantified via 260 nm absorbance on a Nanodrop 2000c (Thermo Scientific, 
Waltham, MA) and diluted to a concentration of 50 ng/μL in RNAase-free water 
(Thermo Scientific).  Reverse transcription was performed with Quantitect RT
Kits (Qiagen) using 500 ng of RNA per reaction.  Resulting cDNA was diluted to
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ntifast 
r sequence R primer sequence 
a concentration of 14.3 ng/μL in Tris-EDTA (Fisher Scientific, Pittsburgh, PA) for 
use in downstream qPCR reactions.  qPCR was performed using Qua
SYBR Green qPCR Kits (Qiagen) using 35.7 ng of cDNA per reaction.   HPRT 
was used as endogenous control. 
Target F prime
HPRT ACT GCT TTC TCG CTA AT 
TGG GCT TAC CTC CCT GGT TCA TCA 
CXCL1 AGA GCT TGA AG GCA TCT TTT GG 
TCA AGA ACA TCC GGA CAC CTT TTA 
IL23A AAA TGT AGG TAC AG 
GGT GGC TCA GGG GAC AGA GCA GGC 
IL12B GTC CAA TG
ACA TCT ACC GAA 
C A 
GGA ATT GTA ATA 
GCG ATC CTG AGC 
IL17A CCT CAG A GAC A 
GCT CCA GAA GGC CTT TCC CTC CGC ATT 
IL22 GTG CTA AA AGG GTG AA 
TCC GAG GAG TCA AGA ACG TCT TCC 
Table 4:  Primers used in qPCR of murine total colonic cDNA   
 Colon histology:  Following sacrifice, the distal portion of the proximal 
colon and the proximal portion of the descending colon were fixed in 10% neutral 
buffered formalin (Thermo Scientific, Waltham, MA) for 7-14 days at room 
temperature.  Colons were paraffin-embedded, sectioned, mounted, and H&E 
stained by the Boston University School of Medicine Experimental Pathology 
Laboratory Services Core facility.  Blinded histological colitis scoring was 
performed using three criteria:  epithelial hyperplasia score (0 = normal, 1 = 
<10% increase in crypt depth, 2 = 10-25% increase in crypt depth, 3 = 25-50% 
increase in crypt depth, 4 = >50% increase in crypt depth), inflammatory 
infiltration score (0 = no inflammatory infiltrates, 1 = infiltrates limited to mucosal 
layer, 2 = infiltrates limited to mucosa and submucosa, 3 = submucosal infiltrates 
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ed on previously used scoring 
methodol Total colitis sc as the s
scores (0 e).      
    re:  Human m HP-1 c
Manassas ere grown in RPM  Healthcare, Marlborough, MA) 
suppleme th 10% fetal bo , Walth
penicillin (Gibco), 50 μg/mL streptomycin (Gibco), and 1X GlutaMAX (Gibco) at 
37°C with 5% CO2.  At passage 5 lls/well were ll 
(Abcam, Cambridge, MA) for 72 hours to promote differentiation into 
macrophage-like cells .   
Stimulation of THP-1 cells with LPS +/- STXs:  Following differentiation of 
THP-1 cells, wells were washed twice with PBS and serum-free RPMI added.  
Serum-free media was removed 24 hours later, wells were washed with PBS 
twice, and RPMI media containing 10% FBS, 50 U/mL penicillin, 50 μg/mL 
streptomycin, and 1X GlutaMAX was added with 100 ng/ml LPS from E. coli 
O127:B8 (Difco, San Jose, CA) +/- 0.1 ng/ml STX1 or 10 ng/ml STX2.  Following 
6, 12, or 24-hour incubations, culture supernatants were collected, flash frozen, 
with focal transmural infiltration, 4 = pronounced transmural infiltration), and 
structural damage score (0 = epithelium intact, 1 = erosions of epithelium 
present, 2 = focal ulcerations of epithelium present, 3 = multifocal ulcerations 
present with granulation tissue) bas
ogy142.  ore was calculated um of individual 
-11 scal
Cell cultu onocytic leukemia T ells (ATCC, 
, VA) w I media (GE
nted wi vine serum (Gibco am, MA), 50 U/mL 
-7, 2-3 x 105 ce  plated in 24 we
plates with RPMI media supplemented with 100 nM phorbol-12 myristate acetate 
143
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bated 
.  
, 
acteria 
 temperature overnight.  Following fixation, STEC 
was w
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sample collection. 
and stored at -80°C. Plate-bound cells were washed with PBS twice and then
lysed using 350 ul of RLT Plus buffer (Qiagen) with 0.143 M β-mercaptoeth
Stimulation of THP-1 cells with fixed STEC:  Stimulation experiment wa
performed replacing LPS from E. coli O127:B8 with formalin-fixed S
86-24 (STX2+, STX1-) and its isogenic STX2-deleted partner strain TUV86-
(STX2-, STX1-).  STEC strains were grown 
rpm shaking overnight.  Serial dilutions were plated on LB agar and incu
overnight at 37°C to determine total number of bacteria in culture prior to fixation
Bacterial culture was spun at 1,000x g for 10 minutes, LB broth was removed
and bacteria were washed with 5 mL of PBS.  PBS wash was repeated and the 
STEC pellet was resuspended in 1 mL of ice cold PBS.  5 mL of ice cold 10% 
neutral buffered formalin was added 1 mL at a time with 15 seconds of vortexing 
after each addition to prevent bacterial aggregation during fixation.  B
remained in fixative at room
ashed twice with 5 ml of PBS, then resuspended in sterile PBS to desired 
concentration for experiments using overnight STEC plates to determine CFUs 
fixed STEC present.  Samples of fixed bacteria were plated on LB agar and 
incubated overnight at 37°C to ensure proper fixation.  Fixed STEC strains w
added to differentiated THP-1 cells at a ratio of 100 bacteria per THP-1 cell in
RPMI media supplemented with 10% fetal bovine serum, 50 U/mL penicillin, 50 
μg/mL streptomycin, and 1% GlutaMAX for 6, 12, or 24-hour incubations prior to 
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RNA w
RNA isolation and RT-qPCR of THP-1 cell samples:  Total RNA was 
isolated using RNeasy Plus Mini Kit in a Qiacube.  500 ng aliquots of isolated 
ere reverse transcribed using a Quantitect RT Kit.  Resulting cDNA was 
diluted to 20 ng/μL in Tris-EDTA.  qPCR was performed using Quantifast SYBR 
Green qPCR Kit for human IL23A, IL12B, and CXCL8 with GAPDH as 
endogenous control.  50 ng of cDNA was used in each qPCR reaction. 
Target F primer sequence R primer sequence 
GAPDH GGT CAT CAT CTC GCT TCC CGT TC 
GGG AGC CAA AAG CCA TGC CAG TGA 
CXCL8 GAA GGA ACC ATT CTC ACT GTC TGT A AGC CCT CTT CAA 
TTA TGA ATT CTC 
AAA C 
IL23A AGA AGC TCT GCA CCA CAC TGG ATA CAC TGG C TGG GGA AC 
IL12B TGG AGA TGC TGG AGC AGG AGC GAA CCA GTA CA TGG CTT AG 
Table 5:  Primers used in qPCR of THP-1 cDNA. 
ELISAs of cell culture supernatants:  ELISAs were performed on cultur
supernatants thawed on ice in 96 well NUNC plates (Thermo Scientific) using 
human READY-SET-GO IL-23 ELISA Kit (eBioscience, Waltham, MA) and 
human IL-8 READY-SET-GO ELISA Kit (eBioscience) according to 
manufacturer’s instructions. 
Results 
DSS colitis resulted in diffusely pale and thickened colons in PBS-
gavaged mice (data not shown).  Gross appearance of DSS+STEC infected 
colons was not appreciably different from DSS+PBS controls, and no evidence of
gross gastrointestin
e 
 
al hemorrhage was observed during necropsy of mice (data 
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colon length was measured at time of euthanasia (3-5 days post-gavage) or experiment 
endpoint (7 days post-gavage).  Means +/- SE shown.  PBS controls (N=9), STEC 86-24 
(N = 12), STEC(ΔSTX2) TUV86-2 (N=12).   
 during DSS colitis and is an indicator of overall 
severity of colitis.  Infection with STX2a-producing STEC strain 86-24 or 
STEC(ΔSTX2) strain TUV86-2 during DSS colitis increased the rate of fecal 
DSS+PBS control mice (Figure 19A+B).  The production of STX2a by STEC 
wn).  Overall colon length is frequently used as a gross marker of col
severity during DSS colitis144.  Mice infected with STX2a-producing strain 86-2
during DSS colitis trended towards shorter colon lengths, but the difference did 
not reach statistical significance (Figure 18).   
 
Figure 18:  STEC infection with STX2 production does not signific
colon shortening during DSS colitis.   
Mice were orally gavaged with STX2-producing STEC strain 86-24, STEC(ΔSTX2) strain 
TUV86-2, or PBS on days 0 and 2 following 5-day exposure to 2.5% w/v DSS.  Tot
 Fecal bleeding occurs
occult bleeding and the duration of positive fecal blood tests compared to 
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uring DSS colitis was associated 
with increased fecal bleeding regardless of STX2a production. 
 
 
 
 
strain 86-24 was not associated with increased fecal occult bleeding compared t
infection with STX2a deletion strain TUV86-2 (Figure 19C+D).  Overall, gross 
markers of colitis did not show a clear effect of STX2a production during 
DSS+STEC infection, though STEC infection d
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Figure 19:  STEC infection increases fecal bleeding during DSS colitis 
independently of STX2 production.   
Mice were orally gavaged with STX2-producing STEC strain 86-24, STEC(ΔSTX2) strain 
TUV86-2, or PBS 0 and 2 days following 5-day exposure to 2.5% w/v DSS.  Fecal 
pellets were collected for fecal occult blood testing daily from infected mice, one 
sample/mouse/day.  A.  Timeline of fecal occult bleeding in PBS controls (N = 9) 
compared to mice infected with either STEC strain 86-24 or strain TUV86-2(N = 24).  B.  
Total percentage of fecal occult blood positive samples from PBS-gavaged mice (N = 46 
fecal samples) and mice infected with STEC strains 86-24 or TUV86-2 (N = 88 fecal 
samples).  C.  Timeline of fecal occult bleeding in STEC strain 86-24 infected mice 
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(N=12) compared to STEC(ΔSTX2) TUV86-2 infected mice (N=12).  D.  Total 
percentage of samples testing positive for fecal occult blood from STEC 86-24 infected 
mice (N = 33 fecal samples) and STEC(ΔSTX2) strain TUV86-2 infected mice (N = 55 
fecal samples).  OG = oral gavage.  Statistical significance determined by Fisher’s exact 
test.  (* - p value < 0.05).   
 Formation of bacterial attaching and effacing lesions in the gastrointestinal 
tract are associated with upregulation of interleukin 23 subunit transcripts (IL23A 
and IL12B) and IL-23 induced IL17A and IL22 transcripts87.  IL-23 axis responses 
thus are an indicator of attachment of STEC to the epithelium and induction of a 
pathogen-targeted host response.  Since DSS colitis produces robust colonic 
inflammation, RT-qPCR of total colonic RNA transcripts for IL23A, IL12B, IL17A, 
and IL22 was performed 2, 4, or 7 days after infection with STX2-producing 
STEC strains TW14359 or 86-24 to determine if a host response to STEC could 
be detected over background DSS-induced inflammation.  CXCL1 transcripts 
, STEC 
lonic 
BS 
 
 
were used as a marker for general colitis severity.  As shown in Figure 20
infection resulted in a general pattern of increased IL-23 axis transcripts 4 days 
after infection.  Surprisingly, STEC infection was associated with reduced co
CXCL1, IL23A, and IL12B transcripts 2 days after infection compared to P
gavaged controls, the timepoint associated with peak inflammatory cytokine
expression in controls. 
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Figure 20:  STEC infection alters time course of colonic IL-23 axis transcript 
production during DSS colitis.   
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Mice were orally gavaged with STX2-producing STEC strains 86-24 or TW14359 0 and 
2 days following 5-day exposure to 2.5% w/v DSS.  Controls were gavaged with sterile 
PBS.  Total colonic RNA was isolated for RT-qPCR for:  A:  CXCL1 B:  IL23A C:  IL12B  
D:  IL17A  E:  IL22  Mean transcript content relative to colonic HPRT +/- SE shown.  
PBS controls (N = 4-8 samples/timepoint), STEC (N = 4-12 samples/timepoint).  
Statistical significance determined by one tailed student’s t test (* - p value < 0.05).  
Significant increases in IL23A and IL17A transcripts were present in mice 
after four days of infection with STEC during DSS colitis compared to DSS+PBS 
mice at the same timepoint (Figure 21).  IL12B and IL22 showed similar patterns 
of increase but did not reach statistical significance.  There was no correlation 
between increased colonic inflammatory transcripts and renal tubular injury of 
mice during STEC infection discussed in Chapter III (data not shown). 
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Figure 21:  STEC infection with STX2 production induces colonic IL-23 axis 
transcript production 3-4 days after infection compared to DSS colitis 
alone.   
Mice were orally gavaged with STX2-producing STEC strains TW14359 (N = 4), 86-24 
(N=8) or sterile PBS (N = 4) following 5-day exposure to 2.5% w/v DSS.  Colons were 
removed for total RNA isolation 3-4 days after oral gavage.  Fold changes normalized to 
average fold change of PBS controls for targets A.  CXCL1  B.  IL23A  C.  IL12B  D.  
IL17A  E.  IL22.  Mean +/- SE indicated.  Statistical significance determined by one tailed 
student’s t test (* - p value < 0.05).  
Though increases in colonic IL-23 axis transcripts IL23A and IL17A were 
detectable over background DSS colitis in the DSS+STEC model, the magnitude 
and time course of transcriptional upregulation was modest compared to findings 
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during C. rodentium infection140.  As previously shown in Chapter III Figure 11, 
STX2a production was associated with delayed clearance of STEC in the 
DSS+STEC model following 4 days of infection, leading us to hypothesize that 
STXs suppress host IL-23 axis responses that contribute to clearance of 
attaching and effacing STEC.  As expected, delayed clearance correlated with 
decreased IL-23 axis colonic transcripts in mice infected with STX2a-producing 
STEC strain 86-24 compared to colons from mice infected with STX2 deletion 
STEC strain TUV86-2 7 days after infection (Figure 22).  Decreases in IL-23 axis 
transcripts 2 days following infection with STX2-producing STEC during DSS 
colitis compared to DSS colitis alone and 7 days after infection with STX2-
producing STEC compared to infection with STEC(ΔSTX2) both suggest that 
STX2 reduces IL-23 related transcriptional responses during STEC infection in 
vivo. 
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 22:  STX2 production during STEC infection reduces colonic IL-23 axis 
transcripts.   
Mice were orally gavaged with STX2-producing STEC strain 86-24 (N=4), STEC(ΔSTX2) 
strain TUV86-2 (N = 9), or sterile PBS (N = 8) 0 and 2 days following 5-day exposure to 
2.5% w/v DSS.  Colons were removed for total RNA isolation 7 days after first oral 
gavage.  Fold changes normalized to average fold change PBS controls for targets  A.  
CXCL1  B.  IL23A  C.  IL12B  D.  IL17A  E.  IL22.  Mean +/- SE indicated.  Statistical 
significance determined by one tailed student’s t test of log fold changes (* - p value < 
0.05). 
 As discussed in Chapter III, the majority of STEC-infected mice were 
euthanized prior to Day 7 of infection due to severe morbidity, unlike mice 
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infected with STEC(ΔSTX2) strain TUV86-2.  Thus, reduced inflammatory 
transcripts in STX2-producing STEC infected colons could be caused by 
selection for mice surviving to 7 days post-infection with reduced disease 
burdens.  Histological scoring of corresponding 7-day post-infection colons did 
not support this reasoning, as colitis in mice infected with STX2-producing STEC 
was more severe compared to mice infected with STEC(ΔSTX2)(Figure 23A).  
Colitis during STX2-producing STEC infection was associated with significantly 
increased epithelial ulceration, as determined by blinded scoring of H&E-stained 
samples (Figure 23B).  By contrast, the difference in epithelial hyperplasia 
(epithelial scoring) and leukocyte infiltration did not reach statistical significance 
(Figure 23C+D).  In the DSS+STEC model, reduced clearance of STX2a-
oducing STEC correlated with worsened colonic epithelial ulceration and 
duced IL-23 axis transcript content after 7 days of infection during DSS colitis 
mpared to  STEC(ΔSTX2a). 
pr
re
co  infection with
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Mice were orally gavaged with STX2-producing STEC strains TW14359 (N = 3) or 86-24 
(N=4) or STEC(ΔSTX2) strain TUV86-2 (N = 10) 0 and 2 days following 5-day exposure 
to 2.5% w/v DSS.  Controls were gavaged with sterile PBS.  Colons were collected 7 
days post infection for histological scoring of H&E stained sections for A.  Overall colitis. 
B.  Epithelial hyperplasia.  C.  Inflammatory cell infiltration.  D.  Structural ulceration and 
erosion.  Statistical significance determined with Kruskal Wallis with Dunn’s post test or 
Mann-Whitney test.  (* - p value < 0.05). 
 Transcriptional evidence of reduced IL-23 axis signaling in the DSS+STEC 
model challenges the current orthodoxy of STXs as pro-inflammatory virulence 
  
Figure 23:  STX2-production worsens gastrointestinal epithelial ulceration during
DSS colitis.   
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factors.  Human macrophage-like THP-1 cells are known to be sensitive to STXs 
in vitro and respond to intoxication by producing the acute cytokines IL-1β, TNF-
α, IL-6 and IL-878,79.  Differentiated THP-1 cells stimulated with formalin-fixed 
STEC strain 86-24 or STEC(ΔSTX2) strain TUV86-2 upregulated transcripts 
encoding IL-8 and IL-23 within 6 hours of stimulation and secreted both IL-8 and 
IL-23 after 12 hours of stimulation (Figure 24).  STEC strain 86-24 induced 
greater IL-23 secretion than STEC(ΔSTX2) strain TUV86-2, presumably due to 
factors other than STX ribotoxicity due to inactivation of toxin by formalin fixation.   
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Figure 24:  Macrophage-like cells secrete IL-23 in response to STEC.   
Differentiated THP-1 cells were stimulated with formalin-fixed STX2-producing STEC 
strain 86-24 or STEC(ΔSTX2) strain TUV86-2 at a 100:1 ratio of bacteria/THP-1 cell.  A.  
Fold changes of CXCL8 and IL-23 subunit transcripts IL23A and IL12B relative to 
baseline transcript content.  B.  Concentrations of secreted IL-8 and IL-23 heterodimer 
from culture supernatants after 12 hours of stimulation determined by ELISA.  Statistical 
significance was determined by two-tailed Student’s t-test.  (N = 3/group/timepoint).  (* - 
p value < 0.05). 
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   Stimulation of THP-1 cells with purified LPS in the presence and absence 
of STX1 or STX2 was performed to isolate the effect of Shiga intoxication on IL-
23 secretion.  As previously reported by other groups145, co-stimulation with 100 
ng/mL of LPS concurrently with 0.1 ng/mL of STX1 or 10 ng/mL of STX2 
increased CXCL8 transcript upregulation after 6 hours (Figure 25A).  Shiga toxin 
exposure increased IL23A transcript after 12 hours of stimulation with LPS, but 
IL12B transcript increased at 12 hours only during STX1 intoxication.  As 
expected, IL-8 protein secretion after 12 hours of stimulation was not affected by 
STX2 intoxication, and minimally reduced by STX1 intoxication (Figure 25B).  In 
contrast, IL-23 secretion was significantly reduced during intoxication with STX1 
or STX2 during LPS stimulation compared to LPS stimulation alone, suggesting 
that STXs selectively inhibit IL-23 secretion without affecting the secretion of 
other acute cytokines.  THP-1 cells continued to secrete IL-8 into supernatant 
over 24 hours regardless of the presence of STXs, indicating that cell death was 
ot the cause of reduced IL-23 secretion (data not shown).   n
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Figure 25:  Shiga toxins inhibit IL-23 protein secretion and alter transcriptional 
upregulation of IL23 subunit transcripts by differentiated THP-1 cells.   
Differentiated THP-1 cells were stimulated with 100 ng/ml LPS alone or concurrently with 
0.1 ng/mL STX1 or 10 ng/mL STX2.  A.  Fold changes of CXCL8 and IL-23 subunit 
transcripts IL23A and IL12B relative to baseline values.  B.  Concentrations of secreted 
IL-8 and IL-23 heterodimer from culture supernatants after 12 hours of stimulation 
measured by ELISA.  Statistical significance was determined by one-way ANOVA with 
Tukey post test.  (N = 3-4/group/timepoint) (* - p value < 0.05, ** - p value < 0.01, *** - p 
value < 0.001). 
  
  
91
Discussion 
 Colonic transcriptional analysis and histopathological findings in the 
DSS+STEC model provide evidence that STX2a production by STEC in the 
gastrointestinal tract inhibits host IL-23 axis signaling and gastrointestinal 
epithelial repair during colitis which in turn delays clearance of STEC.  This 
hypothesis is further supported by suppression of IL-23 protein secretion from 
differentiated THP-1 cells co-stimulated in vitro with LPS and STXs compared to 
stimulation with LPS alone.  These are the first experiments to explore the role of 
the IL-23 axis on STEC clearance in an in vivo model and are one of the few 
studies that suggest that STXs provide a survival benefit to STEC in vivo.  These 
findings demonstrate the utility of the DSS+STEC model to explore host-
pathogen interactions during STEC infection due to the presence of 
gastrointestinal inflammation and resultant host responses not reproduced in 
previously published mouse models of STEC infection. 
 Infection with STX2a-producing STEC reduced IL-23 related colonic 
 
via ex vivo culture of colon tissues from D
culture supernatants was not successful.  Decreases in lymphocyte-associated 
ngly 
inflammatory cytokine signaling pathways can contribute to upregulation of these 
transcripts in the DSS+STEC model, but quantification of IL-23 protein secretion
SS+STEC mice followed by ELISA of 
IL17A and IL22 transcripts support the hypothesis that STX2a reduced IL-23 
production by toxin sensitive cells since these cytokines are known to be stro
induced through IL-23R signaling. This is not entirely conclusive, as other 
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22 producing Th17 cells138,146.  Transcriptional data would be 
thened by future experiments comparing colonic IL-23 axis 
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transcripts in innate lymphocytes and IL-23 is not necessary for the differentiation
of IL-17 and IL-
further streng
transcript content between STEC-infected and STEC(ΔSTX2)-infected colon
four days post-infection.  This timepoint is when STX2a production begins to 
associated with delayed clearance of STEC, and also correlates with peak
transcriptional upregulation of IL-23 and IL-22 production during C. rodentium
infection140.  A more complete assessment of transcriptional changes in the 
DSS+STEC model could also be performed using microarray or Nanostring 
techniques to evaluate alterations in epithelial-produced defense transcripts, 
inhibitory cytokines like IL-10, and other inflammatory transcripts like Ifng.  
Interestingly, IL-23 secretion from macrophages suppresses IL12-induced IFNγ 
activity during C. rodentium infection, and genetic elimination of IL-23 sign
causes increased pathogenicity through IFNγ-mediated inflammation
could occur if STXs suppress IL-23 secretion69.  Colonic intraepithelial and 
lamina propria lymphocyte isolation can reduce variabilit
a is for IL17A, IL22, and other lymphocyte-associated transcripts147.   
 Suppression of IL-23 secretion by human THP-1 cells in vitro is a novel 
finding that challenges the currently held assumption that STXs broadly induce 
acute inflammation in sensitive monocytic cell lines and supports the hypothesis
that STXs inhibit IL-23 secretion by sensitive monocytic cells with downstream
reduction in IL-23 axis signaling within the gastrointestinal mucosa to facilitate 
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STEC persistence.  It should be noted that THP-1 cells are neoplastic cells
may not respond to stimulus in the same way as primary monocytes or 
macrophages, and that differentiation with PMA to induce a macrophage-like 
state may not accurately represent naturally occurring macrophage population
in the gastrointestinal mucosa.  Due to difficulties determining Gb3 conten
cellular subtypes in vivo, the sensitivity to STXs among the various classes of 
monocytic cells is largely unknown, and it is reasonable to assume that dendritic 
cells, macrophages, and circulating monocytes could vary in their response 
STXs in vivo.  The sensitivity of murine monocytes to STXs has not been 
reported in the literature and should be assayed to support in vivo findings w
the DSS+STEC model.   
 The DSS+STEC model successfully establishes colonization with clinic
isolated strains of STEC during colitis with a detectable host IL-23 axis resp
to STEC infection.  Delayed clearance of STX2a-producing STEC correlated with
worsened colonic epithelial damage and reduced IL-23 related transcripts 7 day
following infection compared to infection with STEC(ΔSTX2) in the DSS+STE
model, suggesting that STXs alter host mucosal immune and repair respons
during DSS colitis.  While experiments performed to date do not provide 
conclusive evidence of STX2a inhibition of IL-23 secretion and downstream
23R signaling, they provide an intriguing baseline for future experiments using 
the DSS+STEC model and other model systems to delineate the role of STXs 
during STEC infection.   
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CHAPTER V:  CONCLUSIONS + FUTURE DIRECTIONS 
Limitations of experimental design and findings 
 Experiments colonizing mice with clinical isolate STEC strain TW14359 
during DSS colitis were performed with 6 groups of mice from a single p
STEC colonization with clinical isolate strain 86-24 was determined in three 
different experiments using three separate groups of mice purchased from the 
same provider.  The reproducibility of colonization provides strong evidence of
the effectiveness of the DSS+STEC model to establish gastrointestinal infectio
with STEC in our laboratory.    Mice from providers other than Charles River 
Laboratories were not used in these studies, and future experiments should 
address the susceptibility of other colonies of C57BL/6 mice to DSS+STEC
infection due to the important role of the microbiota in animal models of 
disease148.  Standard labo
homeostasis depending on genetic background and colony conditions, and 
inbred strains of mice vary in their susceptibility to DSS colitis123,149.  Thus, the 
reproducibility of the DSS+STEC model may vary depending on the strain and 
housing conditions of mouse used. 
 STX-induced morbidity and renal injury in the DSS+STEC model was 
evaluated using the clinically isolated O157:H7 STEC strain 86-24 due to an 
available corresponding isogenic STX2a deletion strain (STEC(ΔSTX2) s
TUV86-2) with identical virulence factors other than STX2a production.  These 
strains were acquired after initial experiments to determine colonization dynami
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es 
STX2c.  Virulence fact iffer 
between STEC TW14359 and STEC 86-24, which should be considered when 
comparing morbidity and disease course of DSS+STEC experiments.  
Colonization of the two STEC strains during DSS colitis was similar, and strain 
TW14359 is highly virulent clinically, increasing confidence in the assumption 
that minimal organ invasion and lack of bacteremia during infection with STEC 
TW14359 in the DSS+STEC model is representative of the disease course 
during infection with strains 86-24 or TUV86-2150.       
 Colon cytokine transcripts and histological scoring were performed on 
colons from multiple experiments using either STEC strain TW14359 or STEC 
strain 86-24 with DSS+PBS controls.  This complicates data analysis due to 
imperfect matching of DSS+PBS controls to DSS+STEC samples and increases 
variability seen in colonic cytokine transcripts in DSS+PBS controls.  Future 
experiments exploring host gastrointestinal mucosal responses should include 
consistent numbers of controls for each timepoint in each experimental replicate 
to account for variation in DSS colitis between experiments. 
Exploring mechanisms of DSS-induced susceptibility to STEC colonization 
 Acute colitis induced susceptibility to colonization by STEC, but the critical 
DSS-induced changes in the host gastrointestinal microenvironment facilitating 
colonization have yet to be explored.  Short term DSS exposure results in acute 
and bacterial invasion were performed using STEC strain TW14359.  TW14359
is an O157:H7 strain that produces STX2a like strain 86-24, but it also produc
ors not contained within the LEE pathogenicity island d
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e 
significant colonic epithelial damage and mucosal infiltration
leukocytes, which disrupts host barrier defenses aga
microbiota or potential pathogens like STEC.  Epithelial cells secrete several 
classes of anti-microbial proteins into the gut lumen, and one or more of these 
proteins could be critical for mice to resist STEC colonization.  Reg proteins i
particular have been found to inhibit growth of flagellated bacteria in the gut 
lumen, and are dramatically upregulated during murine infection with C. 
rodentium140,141.  Reg proteins are C-type lectins that are induced following TLR4
or IL-22R signaling in epithelial cells and are associated with bactericidal and
mucosal barrier repair activities in mice151.  Mucin glycoproteins secreted by 
goblet cells form a critical structural barrier to gut microbes, and genetic abla
of mucin production leads to lethal colitis in mice7.  Loss of goblet cells is
component of acute DSS-colitis, and the lack of a mucus barrier may enha
STEC-association with epithelial cells during DSS colitis123.  Healthy host 
intestinal epithelial cells also secrete microRNAs into the gut lumen that have 
been found to alter bacterial growth through inhibitory or enhancing interactions
with microbial DNA, effects that wou
damage during inflammation induced by leukocyte-secreted proteases, 
cytokines, and microbially produced factors could contribute to STEC 
susceptibility through the release of normally restricted nutrients like iron into th
local gut environment, and the iron sequestration protein lactoferrin is known to 
inhibit STEC growth in vivo154.  DSS colitis has broad effects on the host 
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gastrointestinal epithelial barrier, making it likely to have numerous off-target 
effects that do not facilitate STEC colonization but contribute to morbidity.  Use of
genetically manipulated mice lacking individual epithelial barrier components 
could more specifically target pathways responsible for murine resistance to 
STEC colonization with reduced background host abnormalities during 
Identification of murine host factors critical for STEC colonization resistance 
could guide further studies regarding therapies or interventions to improve 
outcomes in STEC patients.      
 While disruption of host barrier functions by DSS likely contributes to 
susceptibility to STEC colonization in the DSS+STEC 
the microbiota should also be considered in future experiments.  During DSS 
colitis in C57BL/6 mice, an outgrowth of commensal E. coli occurred along with
alterations in other bacterial groups compared to the microbiota at 
homeostasis117.  Antibiotic pretreatment and starvation also alter the microbiota, 
and both of these conditions have been reported to induce susceptibility to ST
infection in certain laboratory environments86.  DSS colitis increases abundance
of Bacteroides, a group of bacteria known to secrete sialidases capable of 
cleaving complex sugars into monosaccharide sialic acid resi
with increased sialidase activity in the feces of mice during DSS colitis117.  STEC 
O157:H7 strains do not produce sialidases and cannot metabolize complex 
sugars containing sialic acids, but they are able to utilize free environmental sial
acid as a carbon source125.  Therefore, it is possible that alterations in the colonic
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microbiota with resultant alterations in available nutrients or biochemical 
conditions could contribute to STEC colonization during DSS colitis.   
Germ-free or antibiotic-treated mice can be reconstituted with various 
gastrointestinal microbiota horizontally through fecal transfer or vertically throug
intergenerational maintenance of microbiota in germ-free housing, thus allowing
for the exploration of the role of the colonic microbiota during STEC 
colonization155,156.  Fecal transfer of DSS colitis-associated microbiota int
mice could be sufficient to render mice susceptible to STEC infection with less 
background inflammation than DSS colitis, strengthening the model.  Mice can
stably maintain human gastrointestinal microbiota under germ-free conditions
and experiments determining the role of the human microbiota on STEC 
colonization would be logical if microbiota composition contributes to STEC 
colonization susceptibility in mice157,158.   
The composition of the microbiota alters host barrier homeostasis a
drastically impact host responses to pathogens like STEC, creating a large 
degree of crosstalk between host barrier functions and perturbations in the 
microbiota149,156.  Thus, susceptibility to STEC infection induced by DSS colitis is
unlikely to be caused by a single host factor or microbiota component bu
likely to be due to multifactorial alterations in host microbiome homeos
during colitis.  Nevertheless, delineating the most important mechanisms of 
STEC susceptibility would allow for refinement of the DSS+STEC model via 
minimizing unnecessary alterations in gut homeostasis that do not directly
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contribute to STEC susceptibility and could potentially reveal critical factors th
determine outcomes in STEC patients. 
Mechanisms of delayed clearance of STX2a-producing STEC during DSS
colitis 
 Previously published data suggest that STXs contribute to STEC 
gastrointestinal colonization and survival, but the mechanisms underlying the
benefits of STX production for STEC remain unclear.  In the DSS+STEC m
STX2a-producing STEC strain 8
compared to the isogenic STX2a deletion strain TUV86-2, with differences in
bacterial clearance occurring 4 days post infection and persisting until 
experiment endpoint 7 days after infection.  This difference in clearance was 
previously noted in naïve BALB/c mice infected via high dose gavage with of 
STEC strains 86-24 and TUV86-2, but the colonization was not as r
sustained as occurs in the DSS+STEC model85.  Starved 3 week old mice from 
dams immunized against a Shiga toxin B unit construct were resistant to STEC 
colonization and mortality due to passive transfer of anti-STX IgG and IgA159.  
Reduced STEC clearance during STX2a production was associated with re
colonic IL-23 subunit transcripts IL23A and IL12B and reduced colonic IL-23R-
stimulated lymphocyte cytokine transcripts IL17A and IL22 compared to colons 
from mice infected with STEC(ΔSTX2) 7 days after infection.  The DSS+STE
model was capable of detecting elevations in IL-23 axis-associated transcripts 
during STX2-producing STEC infection over background DSS colitis 4 days after 
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infection, but samples from mice infected with STEC(ΔSTX2) strain TUV8
were not available for comparison at the same timepoint.  Future expe
te the colonic cytokine transcriptional time course of colitis during STE
infection +/- STX production would strengthen the evidence supporting the 
hypothesis that STXs disrupt critical IL-23 derived responses during STEC 
infection.  IL-23 heterodimer secretion has been detected via ELISA 
supernatant of ex vivo cultures of colonic tissues during C. rodentium infection 
but attempts to quantify secreted IL-23 protein in the DSS+STEC model were n
successful to date.  ELISA or Western blots of colonic homogenates for IL-17A,
IL-22, or IL23p19 and IL12p40 would confirm reduced protein production 
suggested by transcriptional data.   
 The hypothesis that STXs reduce IL-23 secretion by sensitive cells to
delay clearance of STEC by the host coul
cking IL-23 subunit or receptor genes, downstream IL-23 axis response 
proteins like IL-17A and IL-22, or epithelial defense proteins like Reg protein
Mice lacking IL-23R expression in intestinal epithelial cells via floxed IL-23R
villin promoter-controlled Cre recombinase expression developed increased 
colonic populations of flagellated bacteria and reduced Reg protein production 
during inflammation, illustrating the importance of the IL-23 signaling in 
responses to luminal Gram negative microbes141.  Resistance to clearance o
STX-deletion strains would be delayed by knockout of elements of the IL-23 a
and clearance of STX-producing strains would be further delayed.  Alternat
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immunological inhibition of IL-23 axis function could be performed with anti-
IL23p19 or anti-IL-22 antibodies, as has
models140.  Rescue of STEC clearance could be attempted by treating IL-23 
deletion
Due to the difficulty in determining cell membrane Gb3 in vivo, the
sensitivity of lymphocyte and monocyte subtypes to Shiga toxins remains poor
characterized.  The DSS+STEC model allows for isolation of colonic 
lymphocytes, macrophages, dendritic cells, and other cell types during STE
infection to determine the effects of STXs on cellular subtype population 
dynamics during colitis.  Flow cytometry could detect phenotypic shifts 
cell populations induced by STEC-produced STXs in vivo, identifying cells 
sensitive to STX-induced cell death or alterations in immune signaling pathwa
caused by Shiga intoxication.  Immunohistochemistry or immunofluorescence
studies of gastrointestinal tissues during STEC infection could provide additional
information regarding the recruitment or geographical distribution of immune cell
within the mucosa and submucosa during Shiga toxicosis.  Of particular interes
would be CD11b+ classical dendritic cells that are the primary source of IL-23 in 
response to C. rodentium infection160.   
Fecal anti-STX IgA content can be assayed as a functional indicator of B 
cell responses to STEC that may contribute to differences in colonization and 
morbidity.  While it is known that STXs are antigenic in animal models and 
patients, the role of anti-STX IgA and IgG production during STEC clearance 
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remains unclear.  Mice orally infected with STEC following an 8 hour period of
starvation developed a specific IgA response that was partially protective against 
future STX2 exposure via injection, but anti-STX IgA did not protect against 
STEC colonization161.  Similar anti-STX antibody production was documente
rabbits exposed to direct toxin injections into ileal loop lumens, with subsequ
toxin-neutralizing mucosal IgA and circulating IgG present 10-14 days follow
exposure162.   
Leveraging the DSS+STEC model to determine the pathogenesis of 
systemic Shiga toxicosis 
  The DSS+STEC model successfully establishes STEC infection du
colitis with a subset of infected mice 
Shiga toxicosis.  This model facilitates investigation of the mechanisms 
underlying the progression of gastrointestinal STEC infection to systemic Shiga 
toxicosis, which could result in new therapeutic targets or interventions for STEC
infection.  Mice exposed to a single oral gavage of STX-producing STEC strain 
TW14359 developed renal injury at a lower rate than mice exposed to two 
gavages with STX-producing STEC strain 86-24, despite similar virulence 
between the two strains in humans.  This suggests that progression to Shiga 
toxicosis is a direct consequence of the dose of STX exposure, which co
tested in the DSS+STEC model via induction of STX production in STEC-infec
mice via administration of antibiotics or mitomycin C19,89.  Quantification of STX 
production via fecal ELISA would provide a time course of STX production in 
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relation to disease status and bacterial clearance15.  Differences in in vivo S
production between STX subtypes and STEC strains can be studied in the 
DSS+STEC model, which may provide insight into the difference in virulence 
between STEC strains in human patients.  Bioluminescent strai
ium have been used to determine colonization and gene expression
dynamics using whole animal or tissue imaging, and a similar approach could be 
used to determine if STX production correlates with colonization state
time course of STX secretion and the overall quantity of STX produced during 
STEC infection remains unclear in human patients and having a better 
understanding of critical time points in the progression to systemic Shiga 
toxicosis can guide therapeutic and diagnostic development.     
While the overall dose of STX could determine outcome in STEC patients,
it is also possible that variation in host responses or gastrointestinal disease 
severity may drive progression to systemic Shiga toxicosis.  During DSS colitis, 
the gut barrier is damaged and disruption of the junctions between epithelial cells 
leads to leaking of luminal proteins into the mucosa.  Fecal occult bleeding 
occurs during DSS colitis with or without STEC infection, indicating disruption of 
epithelial integrity resulting in detectable
n intestinal permeability and Shiga toxin-induced renal injury can be 
further characterized in the DSS+STEC model using oral FITC-dextran assays
fecal albumin measurements, both more sensitive methods of quantifying 
gastrointestinal epithelial barrier function164.  Correlation of increased severity 
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duration of gastrointestinal breach with renal tubular injury in the DSS+STEC 
model would suggest that barrier functions are critical determinants of 
progression to systemic Shiga toxicosis. 
 Circulation of STXs within the bloodstream during STEC infection has 
been difficult to document in patients or animal models, and it remains unclear if 
STXs remain free in the bloodstream or circulate bound to a specific blood 
protein or cell t
interactions, though these results are controversial and have not been 
reproduced by other groups165,16
platelets or red blood cell-derived microvesicles167,168.  The DSS+STEC model 
provides a new tool to explore STX transport in vivo, as circulating leukocyte 
populations can be correlated with disease or impacts on rates of system
toxicosis during depletion of circulating cell types can be determined.   
 The lack of in vivo STEC infection models with gastrointestinal 
inflammation has prevented a complete understanding of the role of host 
inflammation in the development of systemic Shiga toxicosis.  Mice injected
LPS or IL-1β within an hour of STX injection experience increased morbidi
suggesting that acute inflammation increases sensitivity to STXs169.  
Interestingly, mice injected with LPS or IL-1β 20 hours prior to injection with 
STXs were resistant to disease, and LPS tolerant mice were immune to 
increased STX-mediated disease following cytokine or LPS exposure169,170.  
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Rodents treated with dexamethasone or the inhibitor of TNF-α secretion 
anisodamine were resistant to STX-induced disease110,111. 
 The DSS+STEC model includes gastrointestinal inflammation, making 
an excellent tool to explore the hypothesis that host inflammatory respon
increase STX-induced disease.  Concentrations of acute circulating and tiss
cytokines can be correlated with renal tubular injury to determine if systemic 
Shiga toxicosis associates with progression of gastrointestinal disease to 
systemic inflammation.  Anti-inflammatory therapy could be used to determine 
suppression of acute cytokine production results in reduced rates of ren
in the DSS+STEC model, including use of immunological inhibition of spe
acute cytokines.   
houghts 
 The DSS+STEC model is a novel new tool for the study of in vivo 
pathogenesis of host responses to STEC infection, characterization of the effects
of STXs on the host response to STEC, and the elucidation of key components in 
the progression from gastrointestinal STX production during STEC infection
systemic Shiga toxicosis.  It is the first murine model of infection by clinical 
isolate strains of STEC during gastrointestinal inflammation with progression 
renal injury consistent with systemic Shiga toxicosis in the absence of 
bacteremia.  It is also one of the few models that have found a difference in 
colonization dynamics between STX-producing STEC and STEC(ΔSTX), 
indicating that STXs impact STEC persistence during colitis.  Early colonic 
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transcriptional data from the DSS+STEC model suggest that STXs inhibit IL-23
related responses to STEC to prolong STEC survival within the host, w
novel hypothesis in the field.  This hypoth
heterodimer secretion by toxin-sensitive differentiated THP-1 cells exposed to
STXs during LPS stimulation, a finding that challenges the orthodoxy that STXs 
are universally pro-inflammatory virulence factors.  The dissertation work 
establishes a new model of STEC infection and provides a framework for futu
projects characterizing the host gastrointestinal immune response to ST
presence and absence of STXs. 
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